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ABSTRACT
Bacteria are well known to obtain tolerance to antibiotics by forming multicellular structures,
known as biofilms, and by entering dormancy and forming persister cells. Both mechanisms
allow bacteria to tolerate antibiotics at concentrations hundreds to thousands of times higher than
the lethal dose for regular planktonic cells of the same genotype. Persister formation increases in
biofilms; thus, effective control of persister cells, especially those in biofilms is critically
important to infection control. Over the past decades, a bacterial signaling system based on cell
density, named quorum sensing (QS), has been found to regulate biofilm formation and, in
Pseudomonas aeruginosa, the level of persistence.
In this study, we characterized the effects of synthetic brominated furanones, a group of QS
inhibitors, on the persistence of P. aeruginosa and Escherichia coli. Our results revealed that
(Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one (BF8) can reduce persister
formation in P. aeruginosa PAO1 and E. coli RP437 and restore the antibiotic susceptibility of
isolated persister cells at growth non-inhibitory concentrations. In addition to planktonic persister
cells, BF8 was also found to reduce persister formation in the biofilms of P. aeruginosa PAO1
and E. coli RP437.
Study at the genetic level using DNA microarrays demonstrated that BF8 induced the gene mdaB
in both strains and 7 genes encoding oxidoreductases in P. aeruginosa. In E. coli RP437 persister
cells, BF8 was also found to repress the genes for synthesizing indole, a signaling molecule
reported to induce persister formation in E. coli. Interestingly, although BF8 is a QS inhibitor,
the QS signal 3-oxo-C12- acyl homoserine-lactone also rendered the persister cells of P.

aeruginosa PAO1 and its mucoid mutant PDO300 more sensitive to antibiotics. Furthermore,
BF8 was found to have cidal effects on PDO300.
Besides BF8, some other BFs were also found to restore the susceptibility of P. aeruginosa
PAO1 persister cells to ciprofloxacin. Collectively, these results indicate that this group of QS
inhibitors has promising activities to control multidrug tolerant persister cells; and there might be
other bacterial targets of BFs in addition to QS inhibition.
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CHAPTER 1
LITERATURE REVIEW

A part of this chapter has been published as Jiachuan Pan and Dacheng Ren. Quorum sensing
inhibitors: a patent overview. Expert Opin Ther Pat 2009, 19: 1581-1601.
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1.1 Antibiotic resistance on the rise
Although antibiotics have saved millions of lives, more and more antibiotic resistant bacteria
strains are emerging and cause increasing attention. The first methicillin-resistant
Staphylococcus aureus (MRSA) strain was reported in Britain in 19611. Nowadays, “superbugs”
that are resistant to essentially all antibiotics are more and more commonly found in hospitals,
prisons, schools, and nursing homes.
Recently a study published by Infectious Disease Society of America reported that antibioticresistant infections cost the U.S. Healthcare System more than $20 billion annually2. In addition,
antibiotic-resistant infections also results more than $35 billion in societal costs and more than
$8 million due to additional days that patients spend in the hospital. It was estimated that back in
2000, there were 900,000 antibiotic resistant infection cases in the U.S., and this study on 1,391
patients hospitalized shows that 13.5% of patients had antibiotic resistant infections2. For each
case of antibiotic resistant infection, $18,588 to $29,069 more was cost by medicine; 6.4 - 12.7
days more was spent on hospital stay; and the patients had a risk of death two times higher than
the patient without antibiotic resistant infections.
Although antibiotic resistance is naturally occurring based on resistant genes in microbes, misuse
and overuse of antibiotics are considered as important factors that promoted the development and
spread of antibiotic resistance over the years. Poor compliance of patients with the treatment
guidance of antibiotics is also considered as a major factor in increasing rates of bacterial
resistance based on Costelloe’s study3. Clinically, individuals prescribed an antibiotic in primary
care for a respiratory or urinary infection were found to develop bacterial resistance to that
antibiotic.
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Patients with open wounds, implanted medical devices, and weakened immune systems are at
greater risks of infection than the general public. The number of species that cause drug resistant
infections has also been increasing. MRSA was reported to cause 37% of fatal cases of sepsis in
the UK in 1999 while only 4% in 19914. In the US, 50% of all S. aureus infections are resistant
to penicillin, methicillin, tetracycline and erythromycin5. Drug resistant infections are not limited
to Gram positive strains. For example, Pseudomonas aeruginosa, a highly prevalent
opportunistic pathogen was also reported to resist multiple classes of antibiotics6. In fact, P.
aeruginosa is intrinsically tolerant to different antibiotics given by its own multidrug efflux
pumps encoded by antibiotic tolerance genes6. In addition to intrinsic tolerance, by genetic
mutations, or by the horizontal gene transfer of antibiotic resistance genes, P. aeruginosa could
quickly evolve specific resistance. This evolvement of resistance is facilitated by developing
multicellular structures attached to surfaces, named biofilms. Thus, the intrinsic tolerance of P.
aeruginosa is considered as a major reason for developing chronic infections in humans, such as
the patients with cystic fibrosis7.
An alarming fact is that, on one hand, more and more superbugs are emerging by misuse or
overuse of antibiotics; and on the other hand, less and less antibiotics are successfully developed
to obtain the FDA approval8. For example, in the past 50 years, only one new antibiotic class,
daptomycin, was discovered and used clinically8,9. Given this challenge, it is important to
develop new control method to combat the infections that are increasingly difficult to treat.
1.2 Antibiotic resistance vs. antibiotic tolerance
1.2.1 Acquired resistance to antibiotics
Acquired resistance occurs when bacterial strains obtain the ability to resist the activity of certain
antimicrobial agent to which it was previously susceptible10,11. Different from intrinsic resistance
3

that is based on general elements (e,g. efflux pumps) is abroad spectrum of strains of each
species, acquired resistance is developed only when a particular bacterial strain acquires
resistance by vertical mutations or horizontal gene transfer via transformation, transduction or
conjugation12. For example, methicillin-resistant S. aureus (MRSA) is any strain of S. aureus
resistant to β-lactam antibiotics (methicillin, penicillin, dicloxacillin, nafcillin, oxacillin,
cephalosporins)12. Strains sensitive to β-lactams are classified as methicillin-sensitive S. aureus
(MSSA). When S. aureus infection arises, laboratory methods are applied to find out if it is
caused by MRSA or MSSA12.
MRSA strains represent the most studied class of antibiotic resistant strains.13. The mecA gene is
considered as major factor of methicillin resistance in S. aureus; e.g., Ubukata14 reported that a
MSSA strain could be converted to MRSA by the introduction of a plasmid carrying a 4.3-kb
chromosomal DNA fragment encoding the mecA gene from a MRSA strain. With this gene, S.
aureus strain can produce a penicillin-binding protein (PBP) that has relatively low affinity for
most β-lactam antibiotics and it is also reported that absence of PBP in MRSA led to increased
sensitivity to β-lactams. It was also found that additional insertion of a plasmid encoding an
inducible penicillinase can also trigger the expression of MRSA-PBP. It is possible that
penicillinase plasmid contains certain gene(s) required in the mechanism of induction of the
mecA gene but not contained in the 4.3-kb chromosomal DNA fragment14. Thus, production of
PBP may cooperate with other functions such as that of penicillinase to achieve this strong
resistance.
1.2.2

Intrinsic tolerance in individual cells

1.2.2.1 Porin Proteins
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Outer membrane antibiotic uptake/exclulsion mechanisms are considered as a major function for
antibiotic tolerance since the outer membrane acts as a semi-permeable barrier to uptake
antibiotics or substrate molecules6. For example, in P. aeruginosa outer membrane, porin
proteins are required to uptake small hydrophilic molecules such as ampicillin. Hence, the outer
membrane could modulate the movement of hydrophilic antibiotics by changing the activity of
those channels. It has been reported that in P. aeruginosa, the overall outer-membrane
permeability is ranged as 12 to 100 fold lower than other species such as Escherichia coli, which
is consistent with the fact that P. aeruginosa is more tolerant to ampicillin treatment15. Among
all porin proteins known to date, OprF is responsible for about 65-75% of exclusion capacity of
P. aeruginosa outer membrane6.
1.2.2.2 Self promoted uptake
Besides porin protein functions, penetration of outer membrane to antibiotics could also be
achieved by an uptake system named self-promoted uptake which could pump polycationic
antibiotics into the cells6,16. In the self-promoted system, the divalent cation binding sites on cell
surface lipopolysaccharide could be bound by polycationic antibiotics which are much larger
than native divalent cations. And this binding permeabilizes the membrane and pumped more
polycationic antibiotic inside the cells. A shortage of cationic binding site can lead to the low
permeability of polycationic antibiotics. For example, it has been reported that B. cepacia has no
self-promoted uptake system and is tolerant to all polycationic antibiotics17.
1.2.2.3 Efflux pumps
Another mechanism of antibiotic tolerance is through efflux pumps which require proton motive
forces or ATP as energy to exchange the antibiotics through the bacterial membrane. Five classes
5

of efflux pumps are classified based on their features18: small multidrug resistance family (SMR),
resistance-nodulation-division (RND) family, major facilitator superfamily (MFS), ATP-binding
cassette family and multidrug (ABC) and multi antimicrobial extrusion protein family (MATE).
MFS is mostly found in Gram positive bacteria while RND is mostly found in Gram negative
bacteria19. For example, there is no RND found in Mycobacterium tuberculosis; only one RND is
found in Bacillus subtilis; but 4 found in E. coli and 12 in P. aeruginosa. In P. aeruginosa, RND
family attracts more attention for its clinical significance20. Its 12 efflux forms 7 functional
couplings: MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexGHI-OpmD, MexJK, MexXY and
CzrAB-OpmN21,22, which are responsible for pumping out different classes of antibiotics such as
β-lactams, fluoroquinolones, tetracyclines and also small molecules such as acylated homoserine
lactones23, Pseudomonas quinolone signals24 or metal ions25.
1.2.2.4 Enzymes
In addition to efflux pumps, bacteria also have the strategy to degrade antibiotics for survival.
Production of enzymes to degrade antibiotics is one of the methods. The best-known antibioticdegrading enzymes are β-lactamases, which are responsible for bacterial resistance to betalactam antibiotics like penicillins, cephamycins, and carbapenems26. These antibiotics share a
common four-atom ring which could be broken down by β-lactamase26. In P. aeruginosa, βlactamase AmpC enzyme challenges the usage of expanded-spectrum cephalosporins (β-lactam
antibiotic) which now is a well-spread gene in different species such as K. pneumoniae,
Salmonella spp. and P. mirabilis. Besides β-lactamase, kanamycin phosphotransferase has also
been discovered in P. aeruginosa chromosomal DNA.
1.2.2.5 Persister cells with unknown mechanisms
6

Besides the above mechanisms, bacteria can also survive from antibiotic treatment by forming
metabolically inactive cells, known as persister cells7. Such intrinsic tolerance also facilitates the
development of multi-drug resistance through acquired mechanisms, presenting a great challenge
to infection control 27. Since this project is mostly focused on persister cells, more detailed
information about its formation and control will be described in a separated section.
1.3 Intrinsic tolerance based on multicellular behaviors
Besides the tolerance through the above mechanisms in individual cells, multicellular bacterial
communities are also important to chronic infections and the fertilities of acquired antibiotic
resistance28.
Biofilms are complex microbial communities that function as a cooperative consortium, offer
efficient nutrients supply and protect the cells from adverse environment factors28. Inside
biofilms, there are genotypic and phenotypic variants, dispersal cells and dead cells, as well as
extracellular DNA (eDNA), polysaccharide, fatty acid, amyloid fibre, filamentous and phage. All
of these components could help to maintain the structure of biofilms (mushroom-like, tower-like
or wrinkle-like structure) and facilitated the development of biofilms28. Biofilms develop through
several stages: first, free swimming bacteria reversibly attach to a surface and subsequently form
small cell clusters. Then polysaccharides are produced to form mature biofilms with three‑
dimensional structures. Biofilm can also disperse from the surface by certain signal or enzymes
and other factors28. Instead of a single cell or a group of identical individual cells, biofilms are
the most common mode of bacterial life in natural, medical and engineered systems.
In disease conditions, biofilms offer bacteria protection from antibiotics and toxins or immune
factors of the host. Thus, biofilms are considered a major cause for chronic bacterial infection.
7

Both Gram-positive (e.g. Staphylococcus epidermis) and Gram-negative (e.g. P. aeruginosa,
Vibrio cholerae, and E. coli) bacteria are well known to form biofilms29. Biofilm formation is
estimated to be involved in 80% of human infections30 with up to 1000 times higher tolerance to
antibiotics than planktonic counterparts. The persister cells embedded in biofilms also play an
important role in chronic infections with high mortality and morbidity31, e.g., chronic lung
infections in cystic fibrosis patients 32.
1.3.1 Bacterial quorum sensing systems
Since the discovery in 1960s 33, a cell-cell signaling system known as quorum sensing (QS) has
been identified in numerous microbial species

34

. During cell growth of those species, small

signaling molecules are synthesized and secreted into the surrounding environment. As a result,
the local QS signal concentration increases with cell density. When the cell density is above a
certain threshold, a significant amount of signaling molecules

35

bind to intracellular or

membrane receptors and trigger the expression of a series of genes to control a wide spectrum of
phenotypes. The ability to synchronize cellular activities including pathogenesis by QS is
beneficial, and in some cases crucial, for microbes to survive in challenging environments and
establish successful infections. The important roles that QS plays in bacterial pathogenesis also
provides an opportunity to control infections with alternative mechanisms rather than using
antibiotics alone to inhibit growth, which has been seriously compromised by the rapid
development and spread of multidrug resistant microbes 36.
Conceivably, for a QS system to work the cells must be able to synthesize the signaling
molecules, detect the signals through specific molecular interactions, and activate or inactivate
the target genes by responding to the specific signal-receptor binding events. Interruption of any
of these steps could potentially result in repression of virulence and failure for the microbes to
8

infect a host (Figure 1-1). During the last two decades, a number of natural and synthetic agents
have been demonstrated to control QS, which can be categorized as nonpeptide small molecules,
peptides and enzymes including antibodies. Most of these agents inhibit QS and associated
pathogenesis at concentrations non-inhibitory to microbial growth, providing an alternative
approach to controlling microbial infections.
In Gram-negative bacteria, QS systems based on acyl-homoserine lactones (acyl-HSLs or AHLs)
are commonly found. In general, each AHL signal is generated by a synthase (called I protein)
and detected by a specific autoinducer receptor (called R protein). For example, P. aeruginosa
produces and responds to two AHL signals including N-(3-oxododecanoyl)-HSL (OdDHL)
(synthesized by LasI and detected by LasR 37,38) and N-butyryl-HSL (BHL) (synthesized by RhlI
and detected by RhlR

39

). In Vibrio fischeri, three QS signals have been identified including 3-

oxo-hexanoyl-HSL (produced by LuxI and detected by LuxR
required for its synthesis
42,43

41

40

), N-hexanoyl-L-HSL (LuxI is

), and N-octanoyl-HSL (produced by AinS and responded by LuxR

). The specific binding of a QS signal to its receptor is critical for the regulation of gene

expression. For example, the binding of N-3-oxo-C8-HSL to the TraR of A. tumefaciens has been
shown to induce the dimerization of TraR

44

, which then enhances the stability of TraR and

promotes its binding to the promoters of QS-controlled genes 45,46.
All AHLs have a HSL ring, with the length of the acyl side chain varying from 4 to 18 carbon
atoms (Table 1). As demonstrated for P. aeruginosa 47 and V. fischeri 48, short-chain signals such
as BHL could diffuse freely across the cell membrane. In contrast, signals with a long side chain
such as OdDHL of P. aeruginosa

49

need to be exported by efflux pumps 50.
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In addition to AHLs, there is another class of autoinducers in Gram-negative bacteria known as
4-quinolones 51,52. The best studied one is 2-heptyl-3-hydroxy-4-quinolone in Pseudomonas spp.,
and is therefore named Pseudomonas quinolone signal (PQS) 53 PQS is a hydrophobic compound
and requires membrane vesicles to transfer it out of the cell after synthesis 54. In P. aeruginosa,
PQS controls the expression of virulence determinants. The synthesis and activity of PQS are
subject to the regulation of Las and Rhl QS systems
found in other bacteria; e.g., Diggle et al

58

55-57

. Analogues of PQS have also been

reported that Burkholderia pseudomallei, B.

thailandensis, B. cenocepacia, and P. putida produce 2-heptyl-4(1H)-quinolone (HHQ, Table 1)
as a QS signal.
Besides AHLs, there are also other systems developed for both intra- and inter-species QS. AI-2,
derived from S-4,5-dihydroxy-2,3-pentanedione (DPD) with the activity of LuxS, is probably the
most conserved QS signal in bacteria

59,60

. Since the discovery of this system in V. harveyi

homologs of luxS gene have been found in more than 250 bacterial genomes

62

61

,

. LuxS plays a

critical role in AI-2-mediated QS in E. coli, Salmonella typhimurium, and V. harveyi

63,64

. It

catalyzes the formation of DPD, which is then converted to (2S,4S)-2,4-dihydroxy-2methyldihydrofuran-3-one (S-DHMF) and eventually AI-2 molecules 59.
AI-2 has been demonstrated as an interspecies signal for communication among both Gramnegative and Gram-positive species 65. For example, Xavier et al. 66 reported that the wild-type E.
coli is able to uptake AI-2 generated by V. harveyi, and thereby reduce the QS-controlled
bioluminescence in V. harveyi.
In addition to AI-2, some other signals were also found to function in multiple species. For
example, cis-11-methyl-2-dodecenoic acid (DSF, Table 1,

10

67

), was found to control flagellum

synthesis, aerobic respiration and resistance to toxins and oxidative stress in Xanthomonas
campestris

68

, as well as the factors involved in virulence and antibiotic resistance in

Stenotrophomonas maltophilia 69.
1.3.2 Quorum sensing and biofilm formation
Because of the high cell density and genotypic and phenotypic diversity in biofilms, it is
conceivable that a certain signaling system is required for the biofilm to be maintained
chronologically and structurally. Indeed, QS controls biofilm formation in many bacterial species.
QS could take place in these confined bacterial communities and has been an important focus in
biofilm study for at least two decades. For example, it was found that grown in a flow chamber,
P. aeruginosa biofilm contains significantly higher OdDHL concentration (632 µM) than in the
effluent (14nM)

70

. Consistently, it is reported that in P. aeruginosa, the lasI mutant, which is

incapable of synthesizing the QS signal AHL, lost the mushroom-like biofilm structure and
formed a flat and undifferentiated biofilm. In addition, this flat biofilm couldn’t protect the cells
from sodium dodecyl sulphate (SDS) treatment as compared to the wild-type strain71. Although
QS was shown to be a promising target for biofilm control, there is also evidence showing that
the AHLs can function in biofilm life-cycle to disperse mature biofilm. For example, in a study
by Schooling et al72, rhamnolipid, a biosurfactant regulated by QS, was detected in the culture of
P. aeruginosa PAO1 (wild-type) but not in its isogenic homoserine lactone (HSL) mutant P.
aeruginosa PAO-JP2. It was also demonstrated that addition of rhamnolipid into a subculture of
PAO1 reduced its biofilm formation72. Further, the addition of HSL into both PAO1 and PAOJP2 cultures elevated the rhamnolipid level. Therefore, AHL was considered as a potential factor
to disperse biofilm of P. aeruginosa. For Gram positive bacteria, S. aureus biofilm was found to
be dispersed by Agr, a QS signal. For example, higher agr activities were observed during
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biofilm dispersion and agr mutants showed a high propensity to form biofilms. It was observed
that the level of serine protease increased during the dispersion; and the dispersed cells were
found to be more sensitive to the antibiotic rifampicin.73
Like AHLs, AI-2 also plays a role in biofilm formation. Deletion of the luxS gene has been found
to influence the biofilm formation of Streptococcus gordonii

74

and S. mutans

75

; and direct

addition of AI-2 has been shown to induce biofilm formation of E. coli 76.
1.3.3 Biofilm control by QS inhibitors
As discussed above, QS relies on a sequence of events including signal production, detection and
gene activation/inactivation. Interruption of any of these steps could render the QS to fail and
potentially cause detrimental consequences to the survival and pathogenesis of bacteria and fungi.
It is conceivable that eukaryotic organisms may have developed effective strategies to control
QS during evolution. Understanding and improving such strategies with natural or synthetic
molecules could potentially lead to better approaches to controlling microbial pathogens and
associated infections.
1.3.3.1 Brominated Furanones
A group of potent QSIs, brominated furanones, are produced by the marine alga Delisea pulchra
to protect it from adhesion and fouling by marine bacteria. This class of compounds has been
studied extensively both for their activities and the mechanism of inhibition. The best studied
furanone to date is the natural compound (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)furanone (furanone 1, Figure 1-2).
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For Gram-negative bacteria, it is reported that furanone 1 can inhibit the swarming and biofilm
formation of E. coli at concentrations that are non-inhibitory to planktonic growth. The biofilm
formed in the presence of furanone 1 was found to lack the appropriate space between cell
clusters, which was thought to cause the cells to aggregate and die from starvation and
accumulation of metabolic wastes 77.
Several lines of evidence suggest that furanone 1 is an inhibitor of QS based on both AHL and
AI-2. For example, furanone 1 at 10 µg/mL inhibits QS via V. harveyi AHL by 3300-fold, and
QS via E. coli AI-2 by 26,600-fold

77

. Recent studies at the molecular level have shown that

furanone 1 can directly interact with the regulator R protein in AHL QS system 78 and the LuxS
protein in AI-2 QS system79. Such interactions were found to increase the turnover of LuxR in V.
fischeri

80

, render the LuxR of V. harveyi incapable of binding to its target DNAs

78

, and cause

LuxS of E. coli to loose its activities in AI-2 synthesis79. The inhibition of AI-2 QS by furanone
1 is also evidenced by a DNA microarray study, in which furanone 1 was found to repress 56
genes of E. coli and 44 (79%) of these genes were also induced by AI-2

81

. An autoinducer

bioassay indicated that 100 μg/mL furanone 1 repressed AI-2 synthesis in E. coli by 2-fold.
However, the expression of luxS was not affected by furanone 1, suggesting that furanone 1
interrupts AI-2 QS at the post-transcriptional level 81.
To improve the activities of brominated furanones and identify the important structural
components, a number of synthetic furanones have also been studied and some representative
furanones are shown in Figure 1-2. Among them, furanones 3, 4, 6 have been shown to inhibit
QS by increasing the turnover of LuxR

80

. Consistent with the important roles of QS in biofilm

formation, brominated furanones were also found to be biofilm inhibitors

82-84

. Furanone 4 can

cause removal of mature P. aeruginosa biofilms when treating biofilms together with 0.1% SDS
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85

. Although furanone 4 has no effect on P. aeruginosa growth, it can increase the susceptibility

of P. aeruginosa biofilm cells to tobramycin. This antibiotic was found to kill 85-90% of
furanone-treated biofilm cells, while tobramycin alone only kill the top layers of biofilm cells. In
a mouse pulmonary model, furanone 4 was also found to improve the clearance of P. aeruginosa
infection by the mouse immune system 85.
In a recent study 84, several new regioisomers of brominated furanones (e.g., furanones 8, 9 and
10) were synthesized to compare their activities of biofilm inhibition. It was found that the
conjugated exocyclic vinyl bromide on the furanone ring is the most important structural element
for non-growth inhibitory reduction of E. coli biofilm formation. Furanone 8 has also been
described in a patent for its strong inhibition of AHL-mediated QS (demonstrated using a GFPbased reporter), a 90% reduction of AI-2-mediated QS, and a 21% repression of P. aeruginosa
biofilm formation 86.
In addition to the inhibition of AHL- and AI-2-based QS in Gram-negative bacteria without the
inhibition of bacterial growth, some furanones were also shown to inhibit the growth of Grampositive bacteria 86 and fungi 87,88. These findings suggest that some furanones may have multiple
targets of inhibition. Furanone 1 at 40 μg/ml was found to inhibit biofilm formation of B. subtilis
by 25% and reduce the percentage of live cells by 63% 89. Furanones were also found to inhibit
the growth of B. anthracis (e.g., furanones 1, 2, 4 and 5

90,91

), S. aureus (furanones 8 and 11 86)

and fungal pathogen C. albicans (e.g., furanone 1, 8, 9 and 10

87,88

). Surface modification with

furanone 7 was found to inhibit the infection by S. epidermidis in a sheep model 92.
In summary, a relatively large number of brominated furanones have been described. With
activities in QS inhibition

93-95

, antimicrobial activities
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88,96,97

, biofilm inhibition

98

and

antifouling applications of brominated furanones

99,100

. Methods for synthesizing new furanone

compounds 101,102 has also been developed.
1.3.3.2 HSL analogs
Specific signal-receptor binding is critical for gene regulation by QS; thus, it is possible to
develop agonists and antagonists to either stimulate or repress QS by altering the structures of
QS signals. Some analogs of N-(3-oxododecanoyl) L-HSL and butyryl L-HSL were described as
biofilm inhibitors in an early patent by Davis et al.

103

. The structures of these compounds are

shown in Figure 1-3, wherein R1-R21 = CH3, H, OH, NH2, SH or C1-C4 alkyl group, R22-R23 = S
or O; R24-R28 = H or a halogen. These inhibitors compete with OdDHL and BHL for binding to
their receptors, and consequently block the QS and cause inhibition of biofilm formation by
Gram-negative bacteria, e.g. P. aeruginosa.
A group of AHL analogs with a general structure represented in Figure 1-4A was also developed
as QSIs, in which X= O, S, NH or CH2; R1, R2, R3 = H, C1-C12 acyclic aliphatic group, etc

104

.

For example, three of such compounds shown in Figure 1-4 (B, C and D) were identified by
screening AHL libraries using three QS reporter strains constructed with TraR of A. tumefaciens,
LasR of P. aeruginosa, and LuxR of V. fischeri, respectively. These compounds can significantly
inhibit TraR of A. tumefaciens and LasR of P. aeruginosa, while compound 4E also inhibits
LuxR of V. fischeri. In addition to QS, compounds 4B and 4D also exhibited strong inhibitory
effects on P. aeruginosa biofilm formation 105,106.
Another library of HSL analogs was constructed and screened for AHL inhibitors using GFPbased reporters by Suga and coworkers

107,108

. Structures of representative inhibitors are as

shown in Figure 1-5A-H and all of them can reduce QS-mediated GFP expression by at least
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50%. It was found that the position of H bond acceptors, such as hydroxyl, carboxyamide or
pyridyl group, is important for the inhibitory effects.
1.3.3.3 Sulfide AHL analogues
The synthetic compound N-(heptylsulfanylacetyl)-L-HSL (Figure 1-6) has been shown as a
potential QSI109. It is hypothesized that when N-(heptylsulfanylacetyl)-HSL binds to TraR, it
causes conformational changes so that the β-sheet of TraR is forced to move away from the
functional position and renders the TraR unable to bind to its target DNA. As a result, activation
of the target genes by QS will be blocked by N-(heptylsulfanylacetyl)-HSL 109.
1.3.3.4 Garlic extract
Using a lasB-gfp reporter, garlic extract was found to repress QS-controlled expression of lasB in
P. aeruginosa in a dose-dependent manner 110. For example, at the concentration of 2% (vol/vol),
garlic extract reduced the synthesis of GFP by 2-fold without inhibiting the growth of the
reporter strain, indicating that repression of lasB was by disruption of QS. Interestingly, it was
also found that nearly all of P. aeruginosa biofilm cells were killed when treated with 1% garlic
extract and 340 μg/ml tobramycin simultaneously, while 340 μg/ml tobramycin alone only killed
the cells in a thin top layer. Consistent with this finding, the garlic extract was found to cause
changes in the architecture of P. aeruginosa biofilms. Compared to the heterogeneous biofilms
with typical mushroom-like structures, P. aeruginosa formed flat and undifferentiated biofilms
in the presence of 1% garlic extract. Such structural changes may help explain the enhanced
susceptibility of biofilm cells to tobramycin
Figure 1-7.

109

110

. Some QSIs from garlic extract are shown in

. These compounds were demonstrated to interrupt LuxR-based QS at the

concentrations non-inhibitory to bacterial growth.
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1.3.3.5 Other AI-1 inhibitors
In addition to the classes of AHL inhibitors described above, butyrolactone and acetylbutyrolactone (Figure 1-8) have also been found to repress AHL-mediated QS with no inhibition
of P. aeruginosa growth 111.
1.3.3.6 Inhibitors of PQS
A recent patent

112

described the activities of some analogs of the autoinducer 2-heptyl-3-

hydroxy-4-quinolone, which belongs to the family of 4-quinolone signals. These analogs are
hypothesized to inhibit the PQS QS circuit and the binding of the autoinducer molecules to LasR
and/or RhlR in P. aeruginosa.
1.3.3.7 Analogs of AI-2
A number of AI-2 analogs have been described (Figure 1-9A-I)

113-116

. Consistent with the roles

of AI-2 in QS and bacterial pathogenesis, these AI-2 inhibitors have potential applications in
control of bacterial infections and biofilm formation. Tedder et al

114

reported that some purine

and deazapurine-based AI-2 inhibitors can interact with the MTA nucleosidase, an important
enzyme in AI-2 synthesis. These inhibitors, e.g., compounds B and C in Figure 1-9, can bind to
the MTA nucleosidase tightly and potentially inhibit AI-2 synthesis.
Some AI-2 analogs with structures shown in Figure 1-9D-I were described in a recent patent 115.
These analogs have been found to interrupt QS based on AI-2 using a V. harveyi luminescence
assay. The C2 and C3 groups of these compounds appeared to play an important role in the
activities of QS inhibition. In addition to the above analogs, some boronic acids
analogs 118-121 have also been shown as AI-2 antagonists.
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and DPD

1.4 Persister cells and control.
Bacteria are well known to obtain intrinsic tolerance to antibiotics by forming metabolically
inactive cells, known as persister cells7. Such intrinsic tolerance also facilitates the development
of multi-drug resistance through acquired mechanisms, presenting a great challenge to infection
control 27. Persister formation increases when a culture enters stationary phase. However, the
effects of QS on persister formation have been controversial122. A piece of evidence suggests that
persister formation is influenced by QS was reported by Moker et al 122. In their study, P.
aeruginosa cultures contained larger numbers of persister cells in presence of the QS signal 3oxo-C12-HSL and the pigment PYO (secreted in stationary phase). These signals increased
persister formation significantly in logarithmic P. aeruginosa PAO1 cultures but not in E. coli or
S. aureus cultures. However, there is also evidence supporting the opposite. Kim Lewis7 found
that the persister level remains the same with or without addition of spent medium to an early
exponential culture of E. coli 7. Dörr et al123 suggested that TisA/TisB, a toxin/antitoxin (TA)
module, plays a critical role in persister formation in E.coli. In this SOS-TisB response system,
reactive oxygen species (ROS) triggers SOS response which induces over expression of the TisB
protein. The TisB disrupts the protein motive force, leading to decreased ATP level and
increased persister formation. Although adding spent medium not induce persister formation in E.
coli, there is evidence that QS may at least indirectly affect persister formation.
1.4.1 Persister control
A number of different factors have to be found to promote persister formation, such as toxic
metal ions, oxidants, poor nutrition, high temperature, low pH, and membrane acting agents7,124.
Thus, persister formation may be a strategy for cells to survive in adverse environments and
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ensure the survival of the population from being eradicated by severe environmental conditions.
In a study by Collins and colleges125-127_ENREF_126, it was demonstrated that addition of
antibiotics induced cell death by a common mechanism of oxidative stress that relies on the
production of ROS by activating cellular respiration and releasing iron (Fenton reaction).
Challenged by ROS, bacteria induce the synthesis of antioxidant enzymes such as superoxide
dismutase and catalase or small molecules such as ascorbic acid and glutathione or nitric oxide to
reduce ROS128. Besides, H2S was found to enhance the tolerance to ROS by suppressing the
Fenton reaction and elevating SOD and catalase production129. In addition to oxidative
compounds, ROS could be also generated from the nutrient stress in bacteria to form persister
cells128. According to Collins, persister formation is a result of the balance of ROS and
antioxidants. Thus, the study of ROS may offer new strategies for persister control.
1.4.2 Potential methods to reduce persisters
Increasing number of antibiotic resistant strains has been reported, indicating that antibiotics may
not be an ideal approach for infection control8. Since persister cells are highly tolerant to
antibiotics, new methods to enhance the antibiotic or to reduce the persistence may offer good
opportunity to combat bacterial infections. The current factors reported to reduce the persister
level are resuscitation-promoting factor130, sugar131, O2132.
1.4.2.1 Resuscitation promoting factor
The discovery130 of resuscitation promoting factor (RPF) was considered as a major
breakthrough in the study of dormancy state in Gram positive bacteria. RPF, a 16–17 kDa
protein, was reported to promote the growth of dormant cells of Micrococcus luteus by 100 times
and stimulate the growth of several other high CG Gram-positive strains such as Mycobacterium
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avium, Mycobacterium bovis (BCG), Mycobacterium kansasii, Mycobacterium smegmatis, and
Mycobacterium tuberculosis. Mycobacteria were also found to have multiple proteins which
contain a highly conserved RPF domain and this conserved domain has high-level structural
similarity to lysozyme and soluble lytic transglycosylases. It is consistent with the fact that the
RPF cleaves peptidoglycan. In 2008, it is reported133 that a eukaryotic-like Ser/Thr kinase signals
bacteria to exit dormancy in response to peptidoglycan fragments and the peptidoglycan
fragments are potential germinants in Bacillus subtilis to wake up the dormant spores. Besides
Mycobacteria, the homologues of RPF were also found or predicted to exist in other Gram
positive species, for example, there are clear homologues of the Rpf domain in Streptomyces and
Corynebacteria. Deletion of the two rpf homologues from Corynebacteria did not change the
phenotypical properties. However, the lag phase in mutant was prolonged134.
1.4.2.2 Sugar
Sugar is considered as an important carbon resource for growth. Recently reported, glucose,
mannitol, fructose and pyruvate enabled the killing of E. coli and S. aureus persisters with
aminoglycosides in both aerobic and anaerobic conditions131. For example, survival of persisters
was reduced by 99.9% after 2-h treatment with gentamicin and fructose. It was shown that above
sugars or pyruvate could generate a proton-motive force (PMF) facilitating uptake of
aminoglycoside; however, they couldn’t enhance the killing of persister cells by other classes of
antibiotics, such as fluoroquinolone or β-lactam. For example, the persister level after 4 h
treatment with mannitol and ampicillin or ofloxacin didn’t change compared with the none-sugar
treatment, however, persister level after treatment with mannitol and gentamicin were reduced by
more than 99.9% after 4 h treatment. Interestingly, it was reported in our study that glucose and
mannitol at 10 mM couldn’t reduce the persister level during P. aeruginosa PAO1 growth, and it
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is possible that LB medium offered enough metabolic stimuli to persister cells compared with
addition of glucose or mannitol (10mM)135. However, tested in other conditions, for example,
shown by an in vivo study, sugars enhanced the treatment of chronic infections in a mouse
urinary tract infection model. Allison’s study131 on metabolic stimuli establishes a strategy to
eradicate bacterial persisters based on metabolism pathway, and highlights the importance of
PMF in antibiotic tolerance study which may link to different factors with influence on persister
level, such as pH value.
1.4.2.3 Oxygen
The study of persister control by synergy between sugar and aminogluocse indicates a
connection between NADH and persister level131. Consistently, in a study on dissolved oxygen
and persister levels, NADH was found to be involved132. In the study by Grant et al132, it is found
that reduction in dissolved oxygen (DO) allows persister cells to survive from antibiotic
treatment; while with high levels of DO, all cells can be eradicated by antibiotic treatment. The
effects of DO on persister level is consistent with a study by Collins et al127 that bactericidal
antibiotics induce cell death through the production of ROS. In another study by Grant et al, it
was demonstrated that high DO levels enhance the killing of persister cells due to high
concentrations of ROS; while low DO facilitates persister survival. It was also found that in M.
smegmatis cultures, persister cells treated with high concentrations of DO could be rescued from
antibiotic treatment by adding thiourea, a common reducing agent for peroxides. Consistently,
clofazimine, an antibiotic that can increase ROS level via an NADH-dependent redox cycling
pathway, can also reduce the persister level in M. tuberculosis. The above study132 showed the
promise of ROS in persister control. However, ROS at high level could also damage mammalian
cells. In 1950’s, certain “prodrugs”136 were discovered to treat bacterial infection by ROS. These
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compounds were harmless outside bacterial cells; however, when they entered the bacterial cells,
an enzyme converted them into a toxic form with the similar properties as ROS8. In 1960’s, due
to the lack of study on the target of those prodrugs8, they were not approved to treat bacterial
infection in vivo. Given the increase in biofilm-persister-related chronic infections, prodrugs or
the concept of prodrugs might worth further studies8.
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Table 1. Representative QS signals.
Representative
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Structure
microbial species

AHL

P. aeruginosa 137
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O
N
H

O

R

N-butyryl-HSL
Aeromonas salmonicida 138

R=
N-hexanoyl-HSL

Burkholderia cepacia 138

N-octanoyl-HSL
Vibrio fischeri 40

O

N-3-oxo-hexanoyl-HSL
A. tumefaciens 138

O

N-3-oxo-octanoyl-HSL
P. aeruginosa 47

O

N-3-oxo-dodecanoyl-HSL
R. leguminosarum 108

OH

N-3-oxo-5HSL
p-coumaroylHSL

hydroxyl-C14R. palustris 139
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O
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OH

p-coumaroyl-HSL
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4-quinolone

OH
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H
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2-Heptyl-4-hydroxyquinoline
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Salmonella typhimurium
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Other signals

X. campestris
HOOC

143

cis-11-methyl-2-dodecanoic acid (DSF)
B. cenocepacia 144

HOOC

cis-2-dodecenoic acid (BDSF)
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Figure captions

Figure 1-1. Schematic representation of the general mechanism of QS (A) and the approaches of
QS inhibition (B).
Figure 1-2 Structures of representative brominated furanones

77,78,80,81,84-86,89,92,145

. (Note:

different numbering systems have been used in literature, attention should be paid to the
structures when referring to other publications).
Figure 1-3. General structures of the analogs of N-Butyryl-L-HSL (A) and N-(3oxododecanoyl)-L-HSL (B).
Figure 1-4.

Structures of AHL analogs including the general structure (A) and three

representative compounds 105,106,146
Figure 1-5.
147

Representative inhibitors of AHL (A-H)

107,108

and biofilm formation (I-M)

identified from a library of AHL analogs.

Figure 1-6.

Structure of N-(heptylsulfanylacetyl)-L-HSL.

Figure 1-7.

Structures of quorum sensing inhibitors isolated from garlic extract.

Figure 1-8.

Structures of butyrolactone (A) and acetyl-butyrolactone (B).

Figure 1-9.

Structures of AI-2 analogs

113-115

. E = B, P or S for compound A 113. R=(CH2)2c-

C5H9 and R1=CO2Me or 4-pyridyl for compound B 114
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Chapter 2
REVERTING ANTIBIOTIC TOLERANCE OF Pseudomonas
aeruginosa PAO1 PERSISTER CELLS BY (Z)-4-BROMO-5(BROMOMETHYLENE)-3-METHYLFURAN-2(5H)-ONE

This chapter has been published as below with minor modifications. Jiachuan Pan, Ali Adem
Bahar, Haseeba Syed and Dacheng Ren. Reverting antibiotic tolerance of bacterial persister cells.
PLoS ONE 2012, 7, e45778.
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2.1 Abstract
Bacteria are well known to form dormant persister cells that are tolerant to most antibiotics. Such
intrinsic tolerance also facilitates the development of multidrug resistance through acquired
mechanisms. Thus persister cells are a promising target for developing more effective methods to
control chronic infections and help prevent the development of multidrug resistant bacteria.
However, control of persister cells is still an unmet challenge. We show in this report that (Z)-4bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one (BF8) can restore the antibiotic
susceptibility of Pseudomonas aeruginosa PAO1 persister cells at growth non-inhibitory
concentrations. Persister control by BF8 was found to be effective against both planktonic and
biofilm cells of P. aeruginosa PAO1. Interestingly, although BF8 is an inhibitor of quorum
sensing (QS) in Gram-negative bacteria, the data in this study suggest that the activities of BF8
to revert antibiotic tolerance of P. aeruginosa PAO1 persister cells is not through QS inhibition
and may involve other targets. BF8 can sensitize P. aeruginosa persister cells to antibiotics.
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2.2 Introduction
It is well documented that a small portion of a bacterial population can form metabolically
inactive persister cells (1), which are not mutants with drug resistance genes, but rather
phenotypic variants of the wild-type strain (2) due to unbalanced production of toxins/anti-toxins
(3-6) and other mechanisms related to stress response and translation inhibition (1, 7). This
subpopulation can survive the attack of antibiotics at high concentrations, and when the
treatment is stopped, they can reestablish the population with a similar percentage of cells as
persisters, leading to high levels of antibiotic tolerance (2). Such intrinsic tolerance can cause
chronic infections with recurring symptoms after the course of antibiotic therapy and facilitates
the development and wide spread of acquired multidrug resistance through genetic mutations and
horizontal gene transfer (2). For example, high persistence mutants have been isolated from
cystic fibrosis patients with lung infections (8, 9) and from patients with candidiasis (10).
Persister phenotypes have also been found in Mycobacterium tuberculosis, the bacterium causing
chronic tuberculosis (11). Thus, targeting persister cells may help improve infection control and
prevent the development of multidrug resistant bacteria (12). However, controlling persister cells
is still an unmet challenge.

Conceivably, one approach to eliminating persister cells is to wake up this dormant population
and render them to return to a metabolically active stage. These awakened cells are expected to
become sensitive to antibiotics. In Gram-positive bacteria, a 17-kDa protein, named
resuscitation-promoting factor (Rpf) has been discovered as a potential factor to wake up
dormant cells (13). However, a full wakeup call may cause rapid growth of a bacterial pathogen,
which can lead to adverse progression of infection if the antibiotics are not admitted during the
right window.
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Recently, sugars such as mannitol, glucose, fructose and pyruvate have been shown to generate
proton-motive force and promote the uptake of aminoglycosides by persister cells of Escherichia
coli and Staphylococcus aureus, which led to enhanced susceptibility of persister cells to this
class of antibiotics. The effects were observed within 1 h of incubation, less than what is required
for resumption of full growth (14). However, this approach requires relatively high
concentrations of sugar (e.g. 10 mM) and is limited to aminoglycosides, but not the β-lactam
antibiotic ampicillin and the fluoroquinolone ofloxacin. In addition, sugar molecules can only
wake up persister cells, but cannot reduce persistence during growth (see below).

Compared to these approaches, non-metabolites that can potentiate multiple classes of antibiotics
and also reduce persistence during bacterial growth may be advantageous. It is well documented
that the absolute number of persister cells in a culture increases significantly when the culture
enters stationary-phase and when cells form surface-attached highly hydrated structures known
as biofilms (15-17). Recent research has demonstrated that quorum sensing (QS), bacterial cellcell signaling by sensing and responding to cell density, promotes persister formation in
Pseudomonas aeruginosa PAO1; e.g., acyl-homoserine lactone 3-OC12-HSL and phenazine
pyocyanin, QS signals of P. aeruginosa, can significantly increase the persister numbers in
logarithmic phase cultures of P. aeruginosa PAO1 but not E. coli or S. aureus (18). Thus, we
were motivated to test if targeting such pathways may reduce persistence during bacterial growth
and/or wake up persister cells and revert their tolerance to antibiotics. We found in this study that
the QS inhibitor BF8 has potent activities in persister control, although our data suggest that
these activities may not be through QS inhibition and BF8 may have other targets in P.
aeruginosa (below).
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2.3 Materials and Methods
2.3.1 Furanone synthesis.
(Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one (BF8) was synthesized as described
previously (20), dissolved in absolute ethanol as 60 mg/mL, and stored at 4°C until use. Briefly,
Br2 (6.22g, 38.9 mmol) in dichloromethane (20 mL) was added dropwise into a flask containing
2.53 g (19.5 nmol) alpha-methyllevulinica acid in 20 mL dichloromethane. The mixture was
stirred at 35~40ºC till all the alpha-methyllevulinica acid reacted (based on TLC test); and then
the reaction was interrupted by adding ice (~200 mL). The mixture was extracted with
dichloromethane three times (80 mL each), washed with Na2S2O3 (1 M, 100 mL) to remove
residue Br2, dried with anhydrous sodium sulfate (30 min), filtered with cotton, and then purified
by removing solvent using a rotary evaporator. The crude bromo keto acid was added with
concentrated H2SO4 (98%, 10 mL) and the mixture was heated in an oil bath at 110ºC till all the
crude keto reacted (by checking on TLC plates). The raw product was poured into a beaker with
200 mL ice to stop the reaction. The mixture was extracted with dichloromethane three times (50
mL each), washed once with 80 mL H2O and dried using a rotary evaporator. BF8 was further
purified from other impurities using column chromatography (dichloromethane: hexanes = 1 : 4).
The structure of BF8 was confirmed using 1H-NMR by comparing with reported data (20).
2.3.2 Bacterial strain and growth media.
Planktonic PAO1 cultures were routinely grown in Luria-Bertani (LB) medium (24) which
contains 10 g/L NaCl, 10 g/L tryptone and 5 g/L yeast extract. To minimize the variation in the
level of persistence, all overnight cultures of PAO1 were inoculated using single-use glycerol
stocks (disposed after use to avoid freeze and thaw) prepared from the same batch of PAO1
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overnight culture. The P. aeruginosa QS reporter strain PAO1 mini-Tn5-based PlasB-gfp(ASV)
(23) was routinely grown in modified LB medium containing 10 g/L trypton, 5 g/L yeast extract,
and 4 g/L NaCl. Overnight cultures of V. harveyi BB886 were grown in LM medium (38)
containing 10 g/L tryptone, 5 g/L yeast extract, and 20 g/L NaCl. PAO1 biofilms were cultured
in M63 medium (39) containing 13.6 g/L KH2PO4, 2 g/L (NH4)2SO4, and 0.5 mg/L FeSO4·7H2O,
pH 7, supplemented with 0.3% glucose, 1 mM MgSO4 and 0.5% casamino acids.

2.3.3 Persister isolation.
Treatment with Cip up to 50 µg/mL for 3.5 h has been used to isolated PAO1 persister cells
previously (18). We confirmed recently that treatment with 50 µg/mL Cip for 3.5 h is also
sufficient to kill regular cells of our PAO1 strain since no additional killing was observed with
Cip concentration up to 200 µg/mL (the highest concentration tested, Niepa et al., Biomaterials,
In press). To further confirm that the treatment time is sufficient, we also tested the killing with
200 µg/mL Cip during 6.5 h of incubation. As shown in Figure 2-6, no additional killing was
observed with incubation beyond 1.5 h. Given these results, we chose incubation for 3.5 h with
200 µg/mL Cip to ensure the complete elimination of regular cells. After Cip treatment (200
µg/mL, 3.5 h) of 18-h PAO1 overnight cultures, the surviving persister cells were washed twice
with 0.85% NaCl solution to remove residual antibiotics, and then resuspended in 0.85% NaCl
solution. The isolated persister cells were then used for different treatments as described below.
The cells after each treatment were further treated by supplementing with 200 µg/mL Cip and
incubating for 3.5 h. Then the samples were washed three times with 0.85% NaCl solution to
quantify the number of cells that remained as persisters. The drop plate method described by
Chen et al. (40) was followed to count colony forming units (CFUs).
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2.3.4 Effect of BF8 on AHL-mediated QS in the reporter strain V. harveyi BB886.
A V. harveyi BB886 overnight culture was used to inoculate subcultures in AB medium (22).
BF8 was added at different concentrations (0, 0.1, 0.5, 1, 10, 30, 60 µg/mL) after 5.5 h of growth
at 37oC with 200 rpm shaking. The incubation continued for another 1.5 h. Then the
bioluminescence was measured using a luminometer (20/20n, Turner Design, Sunnyvale, CA,
USA). Meanwhile, the CFU of reporter cells was determined using drop method with LM agar
plates (22, 41) after washing the cells with 2% NaCl solution. This experiment was performed
with two biological replicates and 6 replicates on drop plates were counted for each CFU data
point.

2.3.5 Effect of BF8 on QS in PAO1.
A overnight culture of the QS reporter strain PAO1 mini-Tn5-based PlasB-gfp(ASV) (23) was
used to inoculate subcultures in modified LB medium (23). When the subcultures reached OD600
of 0.8, BF8 was added at different concentrations (0, 5, 10, 15, and 30 µg/mL). Green
fluorescence and OD450 was measured when OD600 reached to around 2.7 by following the
previously described protocol (23) to evaluate the effects on QS in PAO1. This experiment was
conducted in duplicate.

2.3.6 Effects of BF8 on persistence of PAO1.
A PAO1 overnight culture was used to inoculate subcultures (each contained 5 mL LB medium)
to an OD600 of 0.05, which were then supplemented with different concentrations of BF8 (0, 5,
10, 30, 50 and 100 µg/mL). The amount of ethanol (solvent of BF8 stock solutions) was adjusted
to be the same for each sample to eliminate any solvent effect. Samples were taken after 5 h of
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incubation at 37oC with shaking at 200 rpm to count CFU. Meanwhile, the remaining portion of
each sample was added with 200 µg/mL Cip and incubated for 3.5 h at 37oC. The samples were
then analyzed to quantify the number of persister cells by counting CFU. This experiment was
performed with two biological replicates and 6 replicates on drop plates were counted for each
CFU data point.

2.3.7 Effects of D-glucose and D-mannitol.
P. aeruginosa PAO1 subcultures were inoculated with an overnight culture to an initial OD600 of
0.05 in LB medium. The subcultures were supplemented with 10 mM D-glucose, 10 mM Dmannitol or without sugar (control). The total number of viable cells and the number of persister
cells were quantified as described in the experiment of BF8 above. This experiment was
conducted with two biological replicates and 5 replicates on drop plates were counted for each
CFU data point.

2.3.8 Effects of BF8 on antibiotic susceptibility of isolated persister cells.
Persisters were isolated from overnight cultures as described above. After dilution by 50 times
with 0.85% NaCl solution, the persisters were challenged with different concentrations of BF8.
Ethanol (the solvent used for making BF8 stock solutions) was adjusted to be the same in all
samples to eliminate any solvent effect. After incubation for 2 h at 37oC with shaking at 200 rpm,
1 mL of each sample was taken and washed three times with 0.85% NaCl to quantify the total
number of viable cells by counting CFU. The remaining portion of each sample was further
tested to quantify the number of cells that remained as persisters as described above. This
experiment was conducted with two biological replicates and 5 replicates on drop plates were
counted for each CFU data point.
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2.3.9 Synergy with other antibiotics.
Persisters were isolated from overnight cultures as described above, and then incubated in 0.85%
NaCl for 2 h at 37oC with shaking at 200 rpm in the absence or presence of 5 µg/mL BF8. The
amount of ethanol was adjusted to be the same in all samples to eliminate any solvent effect.
After incubation, 1 mL of BF8 treated persister samples and BF8-free controls were added with
and without different antibiotics [25 µg/mL tetracycline (Tet), 25µg/mL gentamicin (Gen),
25µg/mL tobramycin (Tob), 500 µg/mL carbenicillin (Car), 25 µg/mL ciprofloxacin (Cip)] and
incubated for another 3.5 h at 37oC with shaking at 200 rpm. The antibiotic treated persisters
were then washed three times with 0.85% NaCl solution to remove antibiotics and plated on LB
plates to evaluate the killing by antibiotics by counting CFU. This experiment was conducted
with two biological replicates and 5 replicates on drop plates were counted for each CFU data
point.

2.3.10 Effects of N-(3-Oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL).
This experiment was conducted by following the same protocol as that of the effects of BF8 on
isolated persister cells described above. The QS signal 3-oxo-C12-HSL was tested at 0, 1.5, 3, 6,
15, and 30 µg/mL. This experiment was conducted with three biological replicates and 5
replicates on drop plates were counted for each CFU data point.

2.3.11 Effects of BF8 on persister cells in established biofilms.
P. aeruginosa PAO1 overnight cultures in LB medium were used to inoculate subcultures in
M63 medium to an OD600 of 0.05 in glass petri dishes containing 2 cm × 1 cm 304L stainless
steel coupons. After 18 h of incubation, the coupons with established biofilms were transferred to
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a 12 well plate (Becton Dickinson, Franklin Lakes, NJ, USA). Each well contained 4 mL of
0.85% NaCl solution supplemented with different concentrations of BF8 (0, 5, 10, 30, 60
µg/mL). The biofilm samples in 12 well plates were incubated at 37°C for 24 h without shaking.
One mL of medium with detached cells was then sampled from each well, washed three times
with 0.85% NaCl solution and plated on LB agar plates to determine the viability of PAO1 cells
by counting CFU. Meanwhile, 1 mL of medium with detached cells was sampled, added with
200 µg/mL Cip, and incubated for 3.5 h at 37°C to isolate persister cells. Then the samples were
washed three times with 0.85% NaCl solution and plated on LB agar plates to determine the
number of persister cells by counting CFU. To collect the biofilm cells, the coupons were
transferred to 15 mL falcon tubes, each containing 5 mL 0.85% NaCl solution. The biofilm cells
were collected by vortexing the coupons for 1 min and sonicating (Ultrasonic cleaner Model No
B200, Sinosonic Industrial Co., Ltd, Taipei Hsien, Taiwan) for 1 min (repeat once) (42).
Collected biofilm cells were plated on LB plates to count CFU and the rest of the samples were
treated with 200 μg/mL Cip for 3.5 h at 37°C for persister isolation. The isolated biofilmassociated persister cells were washed three times and plated on LB agar plates to count CFU.
This experiment was conducted with three biological replicates and 5 replicates on drop plates
were counted for each CFU data point.

2.3.12 Effects of BF8 on PAO1 biofilm formation.
Biofilms were formed on 2 cm × 1 cm 304L stainless steel coupons in M63 medium. The biofilm
cultures with and without 60 µg/mL BF8 (but with the same amount of the solvent ethanol) were
inoculated with an overnight culture to an initial OD600 of 0.05. After 18 h of incubation at 37oC
without shaking, the coupons were gently washed with 0.85% NaCl solution three times to
remove unattached planktonic cells. The total number of biofilm cells and the number of
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persisters were quantified as described above. This experiment was conducted with three
biological replicates and 5 replicates were counted for each CFU sample using drop plate method.

2.3.13 DNA microarray analysis.
Persister cells were harvested from 18-h cultures of PAO1 (100 mL each) using the same
methods as described above. The isolated persister cells were resuspended in 0.85% NaCl
solution supplemented with 1 µg/mL (3.7 µM) BF8 or with the same amount of ethanol (4.17 µL,
to eliminate the solvent effects). After incubation at 37°C for 1 h, treated persister cells were
collected by centrifugation at 10,000 rpm for 5 min at 4oC, transferred to 2 mL pre-cooled
microcentrifuge tubes and frozen instantly in an ethanol-dry ice bath. The cell pellets were stored
at -80°C until RNA isolation.
To isolate the total RNA, the harvested PAO1 cells were lysed by beating at 4,800
oscillations/min using a mini-bead beater (Biospec Products Inc., Bartlesville, OK, USA) after
adding 0.5 mm glass beads, 900 µL RLT buffer and 1% 2-Mercaptoethanol. The total RNA was
extracted using RNeasy Mini Kit (Qiagen, Austin, TX, USA) with on-column DNase treatment
(RNase-Free DNase Set, Qiagen). The RNA samples were sent to the DNA microarray Facilities
at SUNY Upstate Medical University for microarray (P. aeruginosa Genome Array, Affymetrix,
Santa Clara, CA, USA) hybridization. A total of three biological replicates were tested. Using the
GeneChip Operating Software (MAS 5.0), genes with a p-value of less than 0.0025 or greater
than 0.9975 were considered statistically significant based on Wilcoxon signed rank test and
Tukey Byweight. To ensure the significance of microarray data, an additional criterion was
applied to only select the genes with an expression ratio of 2 or higher from this group as
induced and repressed genes. Microarray data has been deposited in Gene Expression Omnibus
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(GEO: GSE36753), compliant with Minimum Information About a Microarray Experiment
(MIAME) guidelines.
2.3.14 RNA slot blotting.
A total of five genes were tested including PA3523, PA2931, PA0182, PA4167 and PA4943.
Primers were designed to include only small inner regions, varying from 368 bp to 448 bp, of
these genes. Hybridization probes were labeled with DIG-dUTP (PCR DIG Probe Synthesis Kit,
Roche, Mannheim, Germany) in PCR reactions by following the manufacturer’s protocol. Total
RNA was isolated as described in the DNA microarray section above. The blotting and signal
detection were conducted as we described previously (43).

2.3.15 Q-PCR analysis.
To verify if killing of PAO1 cells by Cip led to mRNA degradation in the dead cells, the
expression levels of the house-keeping gene proC were quantified using Q-PCR. Total RNA
was extracted from overnight PAO1 cells before and after 3.5 h of treatment with 200 µg/mL Cip.
Then, 200 ng total RNA was taken from each sample to perform cDNA synthesis by using
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Two primers were used in Q-PCR
including the forward primer CGTGGTCGAGTCCAACGCCG and the reverse primer
GCGTCGGTCATGGCCTGCAT. Relative expression ratios were calculated from triplicate
reactions.
2.3.16 Minimal inhibitory concentration (MIC) of BF8.
Subcultures of PAO1 were inoculated from an 18-h overnight culture to an OD600 of 0.05. BF8
was added at different concentrations (0 - 200 µg/mL) and OD600 at this time point was measured.
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After 24 h incubation at 37°C, the presence and absence of growth were checked by comparing
the OD600 before and after incubation. The results indicate that none of the tested concentrations
was sufficient to inhibit growth completely. For example, although growth inhibition was
observed at 150 µg/mL and 200 µg/mL, significant growth was still present (p = 0.00553 and
0.00395, respectively). Therefore the MIC was found to be higher than 200 µg/mL (shown in
Figure 2-5). The experiment was performed with six biological replicates.

2.3.17 Minimal bactericidal concentration (MBC) of BF8.
An 18-h overnight culture of PAO1 was washed and diluted with 0.85% NaCl solution to an
OD600 of 0.05 supplemented with different concentrations of BF8 (0 - 30 µg/mL). After 2 h of
incubation at 37°C in culture tubes, the treated cells were washed and diluted with 0.85% NaCl
solution to count CFU using drop plate method. The results indicate that none of the tested
concentrations was sufficient to kill more than 99.9% of PAO1 (Figure 2-5). Therefore the MBC
(minimum concentration that reduce viability by 99.9%) (26, 27) was found to be higher than 30
µg/mL (Figure 2-5). The experiment was performed with 2 biological replicates.

2.3.18 Viability of PAO1 cells challenged with different concentrations of Cip.
An overnight culture of PAO1 was incubated with 200 µg/mL Cip in 37oC on 200 rpm shaker.
At different incubation time point (1.5 h-6.5 h), Cip treated cells was sampled, washed by three
times, diluted and plated on LB agar plates to determine CFU. The experiment was performed
with 2 biological replicates.
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2.3.19 Transcription level of the housekeeping gene, proC.
Same amount of total RNA extracted from persister cells (after Cip treatment) and total cells
before Cip treatment were reverse transcribed and used in Q-PCR reactions to compare proC
mRNA levels. The persister cell sample was found to have 85.5% less proC compared to that of
total cells before Cip treatment.

2.4 Results
2.4.1 BF8 is a QS inhibitor.
A wide variety of molecules have been discovered as quorum sensing inhibitors (19). We
reported recently that several new synthetic brominated furanones (derivatives of natural
brominated furanones) are inhibitors of biofilm formation (20) and quorum sensing (21) in
Gram-negative bacteria. Among these compounds, (Z)-4-bromo-5-(bromomethylene)-3methylfuran-2(5H)-one (BF8, Figure 2-1A) is the most effective biofilm inhibitor of E. coli and
P. aeruginosa at growth non-inhibitory concentrations (20). It is also a potent inhibitor of
quorum sensing based on AI-2 (21). In this study, the effects of BF8 on AI-1 mediated QS were
studied using the reporter strain Vibrio harveyi BB886 (ATCC# BAA-1118) (22). By monitoring
the bioluminescence and colony forming units (CFU) of the reporter strain, BF8 was found to
inhibit QS at concentrations not inhibitory to the viability of the reporter strain. For example, 10
µg/mL BF8 completely inhibited AI-1-mediated QS with no effects on the viability of V. harveyi
BB886 (Figure 2-1B). To specifically test if BF8 is also an inhibitor of QS in P. aeruginosa, the
expression of the QS-controlled toxin gene, lasB, in the presence of different concentrations of
BF8, was characterized using the reporter P. aeruginosa PAO1 mini-Tn5-based PlasB-gfp(ASV)
by following the procedure described previously (23). As shown in Figure 2-1C, expression of
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lasB in stationary phase cultures (all around OD600 of 2.7) was significantly inhibited by BF8,
confirming that BF8 is also an inhibitor of QS in P. aeruginosa.
2.4.2 BF8 reduced persistence of PAO1.
To test if BF8 can control persister cells of PAO1, we studied the effects of BF8 (up to 100
µg/mL) on the viability and persistence of P. aeruginosa PAO1 (henceforth PAO1) during 5 h of
growth in Luria Bertani (LB) medium (24). As shown in Figure 2-2A, the total number of viable
cells at the end of incubation was around 3.5×109/mL for all the samples (one-way ANOVA
followed by Tukey test, p = 0.122). Thus, BF8 did not affect the viability of PAO1 directly.
Consistently, the MIC (minimum concentration that prevent growth overnight) of BF8 against
PAO1 in LB medium was found to be higher than 200 µg/mL (Figure 2-5 A). Interestingly, at
the growth non-inhibitory concentrations, the persistence of PAO1 was significantly reduced by
BF8 in a dose-dependent manner; e.g., BF8 at 100 µg/mL reduced the number of persister cells
by 63 times (98.4% reduction) compared to the untreated control (one-way ANOVA followed by
Tukey test, p = 0.0006). The reduction of persistence could lead to better efficacy of antibiotics
[e.g., ciprofloxacin (Cip) as shown in Figure 2-2A] and help prevent the development of
antibiotic resistance. To our best knowledge, this is the first compound known to reduce bacterial
persistence during normal growth.
Sugars have been reported to sensitize persisters to antibiotics (14) and Wang et al. (25) reported
that relatively high concentrations of fructose and glucose reduced the expression of QS-related
gene pqsA and the production of extracellular proteases and pyocyanin in P. aeruginosa. To test
if sugars can also reduce persistence of PAO1 under our experimental condition, we repeated the
above experiment using 10 mM D-glucose and D-mannitol instead of BF8. It was found that,
unlike BF8, incubation with neither of these sugars affected persistence (Figure 2-2B, one-way
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ANOVA followed by Tukey test, p = 0.43). These data suggest that persister control by BF8 is
through a different mechanism than that by sugars.
2.4.3 BF8 reverted the antibiotic tolerance of PAO1.
In addition to reducing persistence during PAO1 growth, BF8 was also found to revert the
antibiotic tolerance of isolated persisters. As shown in Figure 2-3A, treatment with BF8 at all
tested concentrations (0.1, 0.5, 1, and 2 µg/mL) increased the susceptibility of persister cells to
Cip. For example, although BF8 at 0.5 µg/mL did not affect the viability of persister cells, the
antibiotic tolerance of persister cells was reverted since 74.1 ±1.1% of persister cells became
sensitive to Cip compared to the untreated control (One-way ANOVA followed by Tukey test, p
= 0.0005). The effects on persistence reduction increased to 89.8±1.4% when BF8 was added at
2 µg/mL (one-way ANOVA followed by Tukey test, p = 0.0013) (Figure 2-3A). At higher
concentrations, however, BF8 was found cidal to PAO1 persister cells. For example, treatment
with 10 µg/mL BF8 led to significant killing of PAO1 persister cells (data not shown),
suggesting that a threshold concentration may exist between growth non-inhibitory reverting of
persistence and cidal effects on persister cells. Consistently, BF8 at 2 and 5 µg/mL did not affect
the viability of regular PAO1 cells in stationary phase (one-way ANOVA followed by Tukey test,
p = 0.7975 and p=0.8572, respectively, Figure 2-5). It appeared to be cidal to regular cells at 10
µg/mL or higher concentrations (Figure 2-5 B); while the MBC (the minimum concentration that
reduces viability by 99.9% (26, 27)) was found to be higher than 30 µg/mL (the highest
concentration tested). Overall, the above finding shows that BF8 can revert persistence at
concentrations that do not affect the viability of both persister and regular cells of PAO1 (2 and 5
µg/mL under our experimental condition).
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We chose 0.85% NaCl solution rather than LB medium to test the effects on isolated persisters
because NaCl solution itself does not contain carbon source, allowing the effects on viability to
be tested specifically. The concentrations of BF8 that exhibited activities were significantly
lower in 0.85% NaCl solution than those in LB medium (to test persistence during growth as
described above), presumably because LB medium contains proteins and other large molecules
that may bind to BF8 and decrease its activity. It is also worth noticing that the persister numbers
are higher in Figure 2-3 (start CFU/mL as 2.1×106 ± 3.1×105 in 3A, 2.3×106 ± 5.7×104 in 3B,
and 2.0×106 ± 4.0 ×105 in 3C) than those in Figure 2-2 (5.0×105 ± 1.7×105/mL for the control)
because the persister cells in Figure 2-3 were isolated from overnight cultures (known to have
higher persistence (28, 29)) and those in Figure 2-2 were isolated from the growing cultures.

It is also interesting that, unlike sugars which can only potentiate aminoglycosides (14), BF8 was
found to restore susceptibility of PAO1 persister cells to both ciprofloxacin and tobramycin
(from two different classes of antibiotics). In total, five antibiotics were tested to evaluate the
effects on antibiotics with different targets including protein synthesis [tetracycline (Tet),
gentamicin (Gen) and tobramycin (Tob)], cell wall synthesis [carbenicillin (Cab)], and functions
of DNA gyrase (Cip). In addition to Cip (t test, p = 0.0095), BF8 at 5 µg/mL was also found to
potentiate Tob (t test, p = 0.0271), while the effects on Tet (t test, p = 0.4096), Gen (t test, p =
0.0771), and Car (t test, p = 0.1976) were not statistically significant (Figure 2-3B).

Since QS is known to stimulate persister formation in PAO1 and BF8 is a QS inhibitor, we
further tested if persister controlled by BF8 can be relieved by the QS signal. It was interesting to
find that addition of 3-oxo-C12-HSL (Sigma-Aldrich, St. Louis, MO, USA) was not able to
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reduce the inhibitory effects of BF8 (Figure 2-3C). Instead, 3-oxo-C12-HSL was also found to
sensitize isolated persisters to Cip in a dose dependent manner. For example, after treatment with
30 µg/mL 3-oxo-C12-HSL for 2 h, nearly all the isolated persisters were killed by 200 µg/mL Cip
(Figure 2-3C). Interestingly, this AHL was found previously to promote PAO1 persister
formation in exponential phase (different experimental condition than described here) (18). Thus,
this QS signal may have different effects on PAO1 persisters under different conditions. These
findings suggest that, although BF8 is a QS inhibitor, the activities of BF8 to sensitize PAO1
persisters to antibiotics is not through QS inhibition and there are other targets of BF8 in PAO1
persister cells.

2.4.4 Effects of BF8 on PAO1 biofilms and associated persister cells.
Compared to planktonic cells, surface-attached bacterial biofilms are more challenging to
microbial control since they are up to 1000 times more tolerant to antibiotics than planktonic
cells and are known to harbor a high percentage of persister cells (1, 30). To understand if BF8
can also control persisters in biofilms, we treated 18-h PAO1 biofilms formed on 304L stainless
steel coupons with different concentrations of BF8 for 24 h. Both the planktonic (detached cells)
and biofilm populations that remained attached were analyzed to evaluate the viability and
persistence of PAO1 with and without BF8 treatment. As shown in Figure 2-4A, BF8 dispersed
established biofilms and reduced the number of persister cells in both biofilm and detached
population. For example, the number of viable cells remained attached after treatment was
reduced by 5 µg/mL BF8 from 3.3×108±1.7×108/cm2 to 7.1×107±1.4×107/cm2 (one-way
ANOVA followed by Tukey test, p = 0.0025). Among the cells that remained attached, the
number of persisters was reduced from 9.6×105±9.1×104/cm2 to 7.0×105±1.1×105/cm2 (one-way
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ANOVA followed by Tukey test, p = 0.002). At concentrations up to 10 µg/mL, BF8 did not
exhibit cidal effects but reduced the percentage of persister cells (0.14±0.01% without BF8 vs.
0.013±0.002% with 10 µg/mL BF8, one-way ANOVA followed by Tukey test, p = 0.0002) in
the detached population (the total number of cells in suspension increased compared to the
control due to detachment); while at high concentrations, BF8 appeared to be cidal to both
regular and persister cells. For example, treatment with 60 µg/mL BF8 for 24 h led to 94.2±5.1%
reduction of viable persister cells remained on the surface (one-way ANOVA followed by Tukey
test, p = 0.0004), although the persisters/regular cells ratio in biofilms was not reduced by BF8
(Figure 2-4A). In addition to the effects on established biofilms, BF8 at 60 µg/mL added at
inoculation was also found to inhibit PAO1 biofilm formation (incubated for 18 h) by 99.1 ±
0.2% (t test, p = 0.0001) and reduced the number of biofilm-associated persisters by 99.2 ± 1.3%
(t test, p = 0.001) (Figure 2-4B).
2.4.5 DNA microarray analysis.
It was an interesting finding that BF8 can render persisters sensitive to the antibiotics targeting
30S ribosome RNA (Tob), and topoisomerase (Cip). The capability to sensitize persister cells to
antibiotics that target both DNA replication and protein synthesis suggests that BF8 may have
made the cells leave the persister stage. To obtain a deeper insight at the genetic level, we
investigated the effects of BF8 on sensitization of PAO1 persister cells using DNA microarrays.
The gene expression profiles of PAO1 persister cells treated with and without BF8 at 1 µg/mL
for 1 h were compared in triplicate. We chose this effective, but relatively low, concentration of
BF8 (as shown in Figure 2-3A) so that the most important genes induced by BF8 can be
identified. The persister cells were isolated by killing regular cells with 200 µg/mL Cip for 3.5 h.
Because average half-life of bacterial mRNA is only a few minutes (31), we expect that the
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mRNA in dead cells should be degraded when the cells were harvested. Consistently, we found
that 85.5% of the mRNA of the house-keeping gene proC was degraded in the persister sample
compared to the sample before Cip treatment. Furthermore, since the identical persister cell
samples were used for both the control (no BF8) and test (with BF8), only the differentially
expressed genes in live cells are expected to be seen in the microarray data.

In total, 28 genes were consistently induced by BF8 by more than 2 fold compared to the control
in all three biological replicates (see Table S1 for the full list). In comparison, although a
relatively small set of repressed genes was seen in each set, no gene was significantly repressed
in all three sets mostly due to low expression ratios in some dataset(s) (test/control < 2.0). This is
possibly because persister cells only have low level expression of essential genes due to their
dormant nature (32, 33). To validate the DNA microarray results, we conducted RNA slot
blotting for five representative genes including one unchanged gene (PA4943) and 4 induced
genes (PA3523, PA2931, PA0182 and PA4167). The results of all blots were consistent with the
microarray data (Table S2). The consistently induced genes encode oxidoreductases (PA4167,
PA1334, PA0182, PA2932, PA2535, PA3223, PA1127), transcriptional factors (PA4878,
PA1285, PA3133, PA2196), and hypothetical proteins (PA4173, PA0741, PA1210, PA3240,
PA2575, PA0565, PA2580, PA2610, PA2839, PA0422, PA1374, PA2691). Since many
reductases are involved in metabolism, our DNA microarray data indicate that some cellular
activities or membrane functions of PAO1 persisters can be induced by low concentrations of
BF8. In addition, the gene PA2931 was induced by 11 times. This gene encodes a repressor of
Cif, a P. aeruginosa toxin that causes degradation of the cystic fibrosis transmembrane
conductance regulator (CFTR) in mammalian cells (34, 35). The induction of PA2931 indicates
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that BF8 can potentially repress the pathogenicity of PAO1. No QS genes were found to be
differentially expressed by BF8. This is not surprising since persister cells are relatively dormant
and are not expected to have QS activities. This finding further supports that persister control by
BF8 involves other pathways and confirms that the mRNAs of differentially expressed genes
were indeed from persister cells.
2.5 Discussion
In this study, we show that BF8 can act synergistically with antibiotics to enhance killing of P.
aeruginosa PAO1 persister cells. Although more work is needed to reveal the exact mechanism,
the restoration of antibiotic susceptibility of PAO1 persister cells at growth non-inhibitory
concentrations by BF8 is nevertheless interesting. The DNA microarray data suggest that some
reductases and proteins for small molecule transfer were induced by BF8. We hypothesize that
interaction between BF8 (at growth non-inhibitory concentration) and cell membrane proteins
can interrupt specific cellular functions, which led to increase in activities of transport proteins
and reductases. Such response should require energy and thus may influence the physiological
stage of persister cells and thus restore their susceptibility to antibiotics. Such effects may be
mechanistically different from natural wakeup when the persister cells are supplied with new
medium. Further study on bacterial membrane potential and metabolism with and without BF8
(at growth non-inhibitory concentrations) can help test this hypothesis. In an earlier work, Shah
et al. (33) compared gene expression in regular cells and persisters of E. coli and found that
around 5% of genes are differentially expressed between these two populations. A number of
genes involved in toxin-antitoxin module proteins rather than stationary-phase-specific functions
were induced in persisters compared to regular cells. In our PAO1 microarray data, however,
only a short list of genes was induced by BF8, which is different from that of regular cells vs.
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persister cells (33). These data confirmed that treatment with BF8 was not leading to a full
wakeup. Because the cells only activated certain functions, such treatment can be advantageous
compared to full wakeup that leads to normal cell growth and potentially higher virulence.
Molecules with such activities may have a good opportunity to be applied either before or
together with antibiotics to clean infections, without a specific window required for antibiotics to
be administered.

To be applied for disease control, it is important to evaluate the safety and efficacy of BF8 in
vivo. This is part of our ongoing work. Nevertheless, some other brominated furanones have
been shown to be safe and effective in animal models such as shrimps (36) and mice (37). For
example, furanone C-30 has been shown to reduce the virulence of P. aeruginosa and help clear
infection from the lungs of mice (37). The activities of persister control found in the present
study bring new opportunities to develop more effective therapies based on this class of
compounds.
In summary, the results described above indicate that BF8 can reduce persistence during the
growth of PAO1 and can also restore the susceptibility of isolated persister cells to antibiotics.
This appears to be a promising advantage of BF8 for persister control. The exact targets of BF8
and the chemical nature of such interaction are unknown and are a goal of our ongoing work. It
is important to understand if there are a set of specific membrane proteins, activation of which
can lead to higher antibiotic susceptibility; and if a subset of such proteins is sufficient for the
observed activities. Better understanding of the underlying mechanism will help develop more
effective methods to control bacterial persistence and associated chronic infections.
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Table
Table 1. List of BF8-inducded genes in PAO1 persister cells. A total of three biological
replicates were tested. The genes induced by more than 2 fold in all three data sets are listed
below.
Induced gene

Expression ratio

Gene products/Functions

PA4167

510.6

2,5-diketo-D-gluconate reductase B

PA1334

227.6

oxidoreductase

PA4173

36.7

hypothetical protein

PA0182

97.1

3-ketoacyl-(acyl-carrier-protein) reductase

PA2932(morB)

64.9

morphinone reductase

PA0741

16.5

hypothetical protein

PA1210

21

hypothetical protein

PA3240

14.4

hypothetical protein
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Resistance-Nodulation-Cell Division efflux
PA3523

9.6

membrane fusion protein precursor

PA2535

9

oxidoreductase

PA2575

9.1

hypothetical protein

PA2931

11

CifR

PA0565

12.8

hypothetical protein

PA2580

8.3

hypothetical protein

PA2610

7.2

hypothetical protein

PA2839

11

hypothetical protein

PA0422

4.2

hypothetical protein

PA3223(acpD)

4.8

AzoR3, azoreductase 3

PA1374

3.4

hypothetical protein

PA3920

3.9

metal transporting P-type ATPase

PA4878

4.2

transcriptional regulator

PA1285

4.4

transcriptional regulator

PA1470

4.1

short chain dehydrogenase

PA3133

3.5

transcriptional regulator

PA2196

4.8

transcriptional regulator

PA2378

3.1

aldehyde dehydrogenase

PA2691

3.7

hypothetical protein

PA1127

3.4

oxidoreductase
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Table 2. The primers used in RNA slot blotting and the blotting results. PA4943 was unchanged
based on DNA microarray data. All the other 4 genes were induced by BF8 based on microarray
results.

Gene

Primers

Expression ratio based on RNA slot blot

PA4943

GAAACGGTGGCATTCGTC

unchanged

GTTTCCAGCTGGGTCTCG
PA3523

CCAGCAACTGTTCCTCATCG

2 fold induction

CAGGTAGGTGCGCTCGTC
PA2931

CGAGGCGATGGAAATCAG

4 fold induction

GCATAGAAGGTCGCCAACTC
PA0182

CGACATCCTGGTCAACAATG
GGTGATGTAGGCCGCTTC
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2 fold induction

PA4167

GCAGATCTACGGCAACGAG

3 fold induction

GCAAGTAAGGGCTGAGTTCG

Figure Captions
Figure 2-1. Dose-dependent inhibition of AHL-mediated QS by BF8. The structure of BF8
(A) and relative QS activities of V. harveyi BB886 (B) and PAO1 lasB reporter (C) are shown.
To study the effects on QS in V. harveyi BB886 reporter, an overnight culture of V. harveyi
BB886 were diluted 1:5000 in AB medium and supplemented with different concentrations of
BF8 after 5.5 h of incubation. The QS activity of each sample was characterized by normalizing
the bioluminescence of the reporter V. harveyi BB886 with its colony forming unit (CFU) after
another 1.5 h of incubation. Figure 2-1B shows that QS was inhibited by BF8 in a dose
dependent manner. To study the effects on QS in PAO1, the reporter strain PAO1 mini-Tn5based PlasB-gfp(ASV) was cultured till an OD600 of 0.8 and then BF8 was added at different
concentrations. The green flouresence was measured when the cultures reached stationary phase
(OD600 around 2.7). The results show that QS in PAO1 was inhibited by BF8.
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Figure 2-2. BF8 reduced persistence of PAO1 at growth non-inhibitory concentrations. (A)
BF8 reduced persistence of PAO1 cultures during growth. PAO1 was cultured for 5 h in LB
medium supplemented with different concentrations of BF8. The total number of viable cells and
the number of persister cells after the 5 h incubation were quantified. (B) Sugars did not exhibit
the same activities as BF8. The same experimental procedure was followed except that 10 mM
glucose or mannitol was added instead of BF8.

Figure 2-3. BF8 and 3-oxo-C12-HSL reverted antibiotic tolerance of isolated PAO1 persister
cells. The total number of viable cells and the number of cells that remained as persisters of
untreated controls in each graph were normalized as 100% for the convenience of data
comparison across the three experiments. (A) BF8 reverted Cip tolerance of isolated PAO1
persister cells. The harvested PAO1 persister cells were treated with different concentrations of
BF8 for 2 h in 0.85% NaCl solution and the viability of PAO1 was evaluated by counting CFU.
A portion of each sample was then treated with 200 µg/mL Cip to count the number of PAO1
cells that remained as persisters. The start number of persisters was 2.1×106 ± 3.1×105/mL. (B)
Antibiotic susceptibility of PAO1 persister cells treated with and without 5 µg/mL BF8.
Persisters were isolated and treated with or without 5 µg/mL BF8 in 0.85% NaCl solution for 2 h.
The treated cells were then incubated with different antibiotics for 3.5 h to test antibiotic
susceptibility. PAO1 persisters were found to be sensitized to Tob and Cip. The start number of
persisters was 2.3×106 ± 5.7×104/mL. (C) The QS signal 3-oxo-C12-HSL also sensitized PAO1
persisters to Cip. The same procedure as that in Figure 2-3A was followed except that 3-oxo-C12HSL was tested instead of BF8. The start number of persisters was 2.0×106 ± 4.0 ×105/mL.
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Figure 2-4. BF8 is effective against PAO1 biofilms. (A) BF8 dispersed biofilm and reduced
persistence in both biofilm and the detached population. The biofilms were treated with BF8 at
different concentrations for 24 h in 0.85% NaCl solution. (B) BF8 inhibited biofilm formation
and reduced the number of persister cells in biofilms. BF8 was added at inoculation and the
biofilms were cultured for 18 h.

Figure 2-5. Effects of BF8 on growth and viability of P. aerugionsa PAO1. (A) Effects on
growth. LB medium was inoculated with overnight P. aeruginosa PAO1 cultures to an OD600 of
0.05. BF8 was added at different concentrations (0 - 200 µg/mL) and the presence and absence
of growth were followed after 24 h of incubation at 37°C. The results indicate that none of the
tested concentrations was sufficient to inhibit growth completely. Therefore the MIC was found
to be higher than 200 µg/mL in LB medium. (B) Effects on viability. An 18-h overnight culture
of PAO1 was washed and diluted with 0.85% NaCl solution to an OD600 of 0.05 supplemented
with different concentrations of BF8 (0 - 30 µg/mL). After 2 h of incubation, the number of
viable cells was determined by counting CFU. None of the tested concentrations was sufficient
to kill more than 99.9% of PAO1. Therefore the MBC was found to be higher than 30 µg/mL in
0.85% NaCl solution.

Figure 2-6. Effects of Cip treatment time on PAO1 killing. An 18-h overnight culture of
PAO1 was treated with 200 µg/mL Cip for different lengths of time to determine the required
treatment time for persister isolation.

76

Figure 2-7. Transcription level of the housekeeping gene, proC, from total cells (before Cip
treatment) and persister cells quantified with Q-PCR. The persister cells were isolated
following the same procedure as described in the manuscript. The cells before and after Cip
treatment were used to isolate total RNA and compare the transcription level of proC.
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Chapter 3

(Z)-4-BROMO-5-(BROMOMETHYLENE)-3-METHYLFURAN2(5H)-ONE SENSITIZED Escherichia coli PERSISTER CELLS TO
ANTIBIOTICS

85

This chapter has been submitted as below with minor modifications. Jiachuan Pan, Ali Adem
Bahar, Fangchao Song and Dacheng Ren. (Z)-4-bromo-5-(bromomethylene)-3-methylfuran2(5H)-one sensitizes Escherichia coli persister cells to antibiotics. Biotechnology and
Bioengineering. 2013.
3.1 Abstract
Persisters are a small subpopulation of bacterial cells that are dormant and extremely tolerant to
antibiotics. Such intrinsic tolerance also facilitates the development of multidrug resistance
through acquired mechanisms based on drug resistance genes. In this study, we demonstrate that
BF8 is effective against persistence in Escherichia coli. It was found to reduce persistence during
E. coli growth and revert the antibiotic tolerance of its persister cells. The effects were more
profound when pH was increased from 6 to 8.5. Although BF8 is a quorum sensing (QS)
inhibitor, similar effects were observed for the wild type E. coli RP437 and ΔluxS mutant,
suggesting that the effects are not solely through inhibition of AI-2 mediated QS. In addition to
planktonic persisters, BF8 was also found to disperse RP437 biofilm and render the cells more
sensitive to ofloxacin. These findings broadened the activities of brominated furanones and shed
new lights on persister control.

Keywords: antibiotic tolerance, persister, quorum sensing, inhibition, biofilm
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3.2 Introduction
It is well documented that bacteria can tolerate antibiotics by entering dormancy and forming socalled persister cells, or by attaching to surfaces and developing multicellular structures, known
as biofilms (1). Such high level antibiotic tolerance leads to chronic infections and facilitates the
development of multidrug resistance through acquired mechanisms (2); e.g., high persistence
mutants of Pseudomonas aeruginosa and Candida albicans have been isolated from patients
with cystic fibrosis and oral thrush biofilm, respectively (3, 4). Persister formation can result
from unbalanced toxin/antitoxin production (5), SOS response (5), heavy metal toxicity
responses (1, 6) and by cell-cell signaling based on indole (7). Some factors that have been found
to stimulate persister formation include toxic metal ions, oxidants, starvation, high temperature,
low pH, and membrane acting agents such as TisB (1, 5, 8).
Besides persisters cells, biofilm formation is another important strategy for bacteria to survive in
adverse environments. Due to their ubiquitous presence, biofilms are a major form of microbial
life in both natural and disease conditions (9). Biofilm matrix contain extracellular polymeric
substances (EPS) such as extracellular DNA (eDNA), polysaccharides, proteins and amyloid
fibrils which help maintain the biofilm structure and protect the biofilm cells (10). Consistently,
biofilm bacteria are up to 1000 times more tolerant to antibiotics than free swimming cells (11)
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and are involved in 80% of human bacterial infections (12). Persister formation increases in
biofilms and high persister mutants have been isolated from biofilms clinically (3, 13).
Despite the significance, only few studies on persister control have been reported to date. Allison
et al (14) demonstrated that sugars, such as mannitol, glucose, fructose and pyruvate could make
persister cells more sensitive to aminoglycosides. Their study reported that NADPH generated
from sugar is oxidized in the electron transport chain by quinone oxidase, and the proton motive
force (PMF) generated in this process facilitates the uptake of aminoglycosides (14). This
discovery is consistent with the report of Dörr (5) that TisB, a membrane-acting peptide and a
toxin, could decrease the PMF and ATP levels in E. coli; and therefore, increase its tolerance to
antibiotics (15).
Persister formation of different bacteria species (E. coli, P. aeruginosa, Staphylococcus aureus)
has been found to increase when their cultures enter stationary phase (1, 16). However, quorum
sensing (QS), a bacterial cell-to-cell signaling system based on cell density, has only been found
to promote persister formation in P. aeruginosa, but not E. coli. For example, adding spend
medium (supernatant from stationary phase) to early exponential phase cultures of P. aeruginosa
PA14 or 3-oxo-C12-homoserine lactone to early exponential phase cultures of P. aeruginosa
PAO1 led to increased persistence (17). However, spend medium from stationary phase of E. coli
cultures does not affect its persister formation (1).
Since QS promotes persister formation in P. aeruginosa, we recently tested if QS can be a target
for persister control. We evaluated the effects of a synthetic QS inhibitor, (Z)-4-bromo-5(bromomethylene)-3-methylfuran-2(5H)-one (BF8), on the persistence of P. aeruginosa PAO1
(18). This compound was found to reduce persister formation of P. aeruginosa PAO1 and
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sensitize the formed persisters to ciprofloxacin and tobramycin. Interestingly, the QS signal N-(3Oxododecanoyl)-L-homoserine lactone was also found to sensitize P. aeruginosa PAO1 persister
cells under our experimental condition. Thus, the effects of BF8 on P. aeruginosa PAO1
persisters are, at least, not solely through inhibition of QS via N-Acyl homoserine lactones
(AHL).
To further understand this new phenomenon and test if BF8 is also effective against other
bacteria. We tested its effects on E. coli persister cells. We chose E. coli in this study because E.
coli does not produce AHL (19), allowing us to study the effects of BF8 on persisters in the
absence of this class of QS signals at growth non-inhibitory concentrations (Figure 3-6). Also,
we have reported that BF8 is an inhibitor of E. coli biofilm formation (20) and QS based on AI-2
(21). Thus, it can help to understand general vs. specific effects of BF8 in bacteria that can
communicate via AI-2 mediated QS.
3.3 Material and Methods
3.3.1 Furanone Synthesis.
(Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one (BF8) was synthesized as described
previously (18, 20), dissolved in absolute ethanol as 60 mg/mL, and stored at 4°C until use.
3.3.2 Bacterial strains and growth media.
E. coli RP437 (henceforth RP437) and E. coli KX1485 (RP437 ΔluxS, henceforth KX1485) (22)
were routinely grown in Luria-Bertani (LB) medium (23) containing 10g/L tryptone, 5g/L yeast
extract and 10g/L NaCl. LB medium was also used to form biofilms. Persister cells of E. coli
were isolated as described previously (14, 18)_ENREF_14: briefly, an overnight culture was
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treated with 5 µg/mL ofloxacin (Ofl) for 3.5 h at 37oC with shaking at 200 rpm, washed twice
with 0.85% NaCl solution to remove Ofl, and then resuspended in 0.85% NaCl solution. This
condition was confirmed to be sufficient to kill regular cells (Figure 3-7). The drop plate method
described as described previously (24) was followed to count colony forming units (CFUs) and
One-way ANOVA followed by Tukey test was used to test the significance of all results. PBS
buffer used in this study was based on 0.85% NaCl solution with NaH2PO4 and Na2HPO4 added
as pH buffering agents. The ionic strength of pH buffering agents was 10 mM. The pH value was
adjusted as 6, 6.5, 7, 7.5, 8 or 8.5.
3.3.3 Effects of BF8 on persister formation.
A RP437 overnight culture was used to inoculate sub-cultures in 5 mL LB medium with an initial
optical density at 600nm (OD600) of 0.05. The subcultures were then supplemented with different
concentrations of BF8 (0, 2, 5 and 10 µg/mL) immediately. The amount of ethanol (solvent of
BF8 stock solutions) was adjusted to be the same for all samples to eliminate any solvent effect.
Samples were taken after 5 h of incubation at 37oC with shaking at 200 rpm and the total number
of viable cells in each sample was determined by counting CFU using drop plate method as
described previously (24). Meanwhile, the remaining portion of each sample was added with 5
µg/mL Ofl and incubated for 3.5 h at 37oC with shaking at 200 rpm to count the number of cells
that remained as persisters. To compare with the effects of sugars (known to sensitize E. coli and
S. aureus persister cells to aminoglycosides (14)), the same treatment was also tested using 10
mM D-glucose or D-mannitol instead of BF8. To understand if the effect of BF8 on persister
formation is through QS inhibition through AI-2, a luxS mutant (KX1485) was tested under the
same condition.
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3.3.4 Effects of BF8 on ofloxacin susceptibility of isolated persister cells.
Persister cells were isolated from an 18 h overnight culture as described above and diluted by 50
times with 0.85% NaCl solution. Then each 3 mL of diluted persister cells was challenged with
different concentrations of BF8 (0, 0.1, 0.5, 1, 2 and 5 µg/mL). The concentration of ethanol (the
solvent used for making BF8 stock solutions) was adjusted to be the same for all samples to
eliminate any solvent effect. After incubation at 37oC for 2 h with shaking at 200 rpm, 1 mL of
each sample was taken and the cells were washed three times with 0.85% NaCl solution to
evaluate the viability by counting CFU. In addition, the number of cells that remained as
persisters were quantified by counting CFU after treatment with 5 µg/mL Ofl for 3.5h at 37oC.
3.3.5 Synergy with other antibiotics.
Persisters were isolated from 18 h overnight cultures, and treated with BF8 at different
concentrations. After incubation, 1 mL of BF8 treated persister samples or controls (no BF8)
were supplemented with different antibiotics [25 µg/mL tetracycline (Tet), 25µg/mL gentamicin
(Gen), 25µg/mL tobramycin (Tob) or 100 µg/mL ampicillin (Amp)] and incubated for another
3.5 h at 37oC with shaking at 200 rpm. The antibiotic-treated persisters were then washed three
times with 0.85% NaCl solution to remove antibiotics, diluted and plated on LB agar plates to
determine the susceptibility of control and BF8-treated persister cells to different antibiotics.
3.3.6 Synergy with pH change.
Persisters were isolated from 18 h overnight cultures, and then diluted by 50 times with PBS
buffer at different pH (6.0, 6.5, 7.0, 7.5, 8.0 or 8.5) or 0.85% NaCl solution. Then 1 µg/mL of
BF8 was added to the above PBS or 0.85% NaCl solution with persister cells. After 2 h

91

incubation at 37oC with shaking at 200 rpm, 1 mL sample was washed, diluted and plated on LB
agar plates to count CFU. Meanwhile, a part of BF8-treated persister cells was treated with 5
µg/mL Ofl for 3.5 h again to determine the number of cells that remained as persisters. This
experiment was also performed without BF8 as control. To determine if the effects of pH was
due to any permanent change in BF8’s structure, BF8 was first dissolved in PBS with pH 6, at 10
µg/mL. Then the pH was adjusted to be 6.5, 7, 7.5, 8 or 8.5 with NaOH solution, and incubated
at 37oC for 2 h with shaking at 200 rpm. After this treatment, the pH of each sample was adjusted
back to 6 using HCl solution. The amount of NaOH and HCl solution was pre-calculated for
each sample to ensure the final concentration of BF8 to be 1 µg/mL. These solutions were then
tested for their effects on persister cells as described above.
3.3.7 Effects of BF8 on persister formation during biofilm growth.
RP437 overnight cultures were used to inoculate LB medium supplemented with different
concentrations of BF8 (0, 5, 10, 30 and 60 µg/mL) to an OD600 of 0.05. The amount of ethanol
(solvent in BF8 stocks) was adjusted to be the same in all samples to eliminate any solvent
effect. Sterile 2 cm × 1 cm 304L stainless steel coupons were transferred to these cultures to form
biofilms. After 18 h of biofilm growth at 37oC without shaking, coupons with biofilms were
washed gently with 0.85% NaCl solution and soaked in 5 mL 0.85% NaCl solution. The biofilm
cells were mechanically detached by vortexing for 1 min and sonicating (Ultrasonic cleaner
Model No B200, Sinosonic Industrial Co., Ltd, Taipei Hsien, Taiwan) for 1 min (repeat once)
(25). This condition was found to sufficiently detach biofilm cells without affecting cell viability
(25, 26). A portion of detached biofilm cells was plated on LB plates to count CFU and the rest
of each sample was used for persister isolation as described above. In addition to biofilm cells, 1
mL planktonic cells in each subculture was also washed three times and plated on LB agar plates
92

to determine the viability by counting CFU. Another 1 mL of planktonic cells in each subculture
was sampled to count the number of viable persisters after 3.5 h treatment with Ofl at 5 µg/mL,
as described above.
3.3.8 Effects of BF8 on biofilm–associated persister cells.
Biofilms were grown on 304L stainless steel coupons (2cm × 1 cm) in petri dishes as described
above but in the absence of BF8. After 18 h of incubation, the coupons with established biofilms
were washed gently with 0.85% NaCl solution and transferred to a 12 well plate (Becton
Dickinson, Franklin Lakes, NJ,). Each well contained 4 mL of 0.85% NaCl solution
supplemented with BF8 at 0, 2, 5, 10 or 30 µg/mL. The biofilm samples in 12 well plates were
incubated at 37°C for 12 h without shaking. After treatment, 1 mL of suspension was sampled
from each well. The cells were collected by centrifugation, washed three times with 0.85% NaCl
solution, and then plated on LB agar plates to determine the viability of RP437 cells by counting
CFU. Meanwhile, another 1 mL of planktonic sample was collected to quantify the number of
persister cells as described above. To collect the biofilm cells, each coupon was transferred to a
15 mL falcon tube containing 5 mL 0.85% NaCl solution, vortexed for 1 min and sonicated for 1
min (repeat once) (25). The total number of viable cells and number of viable persister cells in
the biofilm population were determined using drop plate method as described above.
3.3.9 DNA microarray analysis.
Persister cells were harvested from overnight cultures of RP437 (100 mL each) using the same
methods as described above. The isolated persister cells were resuspended in 200 mL 0.85%
NaCl solution supplemented with or without 5 µg/mL BF8. The amount of ethanol was adjusted
to be the same for both samples to eliminate any solvent effect. After incubation at 37°C for 1 h,
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treated persister cells were collected by centrifugation at 10,000 rpm for 5 min at 4oC, transferred
to 2 mL pre-cooled centrifuge tubes and frozen instantly in an ethanol-dry ice bath. The cell
pellets were stored at -80°C until RNA isolation, using RNeasy Mini Kit (Qiagen, Valencia, CA,
USA) as described previously (18). The isolated RNA samples were sent to SUNY Upstate
Medical University for hybridization to Affymetrix DNA microarrays. Using GeneChip
Operating Software (MAS 5.0), genes with a p value of less than 0.0025 or greater than 0.9975
were considered as statistically significant based on Wilcoxon signed rank test and Tukey
Byweight. The genes that are induced/repressed in both data sets are listed.
3.3.10 Quantitative real time PCR analysis.
Six genes were selected to further confirm their transcription level using with Q-PCR. These
genes include three induced genes (mdaB, yhhW, ybiJ), two repressed genes (trpD, cspD), and
two genes that were not affected by BF8 (including hcaD and housekeeping gene mdoG).
cDNAs for control and BF8 treated samples were synthesized by using iScript™ cDNA
Synthesis Kit (Biorad, Hercules, CA, USA).
Primers for selected genes were designed using OligoPerfect™ Designer (Life Technologies,
USA) to keep the melting temperatures between 59.9˚C and 60.1˚C and product size between
152-220 bp. The sequences of primers are listed in Table S1.
Q-PCR reaction was carried with an Eppendorf Mastercycler Realplex thermal cycler
(Eppendorf, Hauppauge, NY, USA) and Fast SYBR Green Master Mix was purchased from
Applied Biosystems (Foster City, CA, USA). The following conditions were applied in Q-PCR
reactions: enzyme activation for 1 min at 95˚C followed by 40 cycles with denaturation for 5 s at
95˚C, and annealing/extension for 45 s at 60˚C.
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The DNA microarray data have been deposited in Gene Expression Omnibus (GEO: GSE44273)
3.4 Results

3.4.1 BF8 reduced persister formation during E. coli growth in LB medium.
The subcultures of RP437 were treated with BF8 for 5 h in LB medium at growth-non inhibitory
concentrations (0, 2, 5 or 10 µg/mL). As shown in Figure 3-1A, at 2 µg/mL, BF8 reduced
persistence by 63.9±5.0% compared to BF8-free control (p= 0.0047); while at a higher
concentration of 10 µg/mL, BF8 reduced persistence by 83.5±1.2% (p=0.0018). Consistent with
what we found for P. aeruginosa (18), 10 mM of mannitol and glucose, which were reported to
sensitize E. coli persister cells to aminoglycosides (14), did not exhibit the same effects as BF8
(p = 0.9273) (Figure 3-1B). Since BF8 is an inhibitor of AI-2 mediated QS (21), we also tested
its effects on an AI-2 mutant to understand if the effects of BF8 were specifically through AI-2
inhibition. The persister levels of RP437 and its ΔluxS mutant in 5 h cultures were found to be
the same (Figure 3-8). As shown in Figure 3-1C, BF8 at growth non-inhibitory concentrations
also reduced persistence of the ΔluxS mutant (KX1485) during 5 h incubation. For example, at
10 µg/mL, BF8 didn’t reduce the growth of KX1485; however, the number of persister cells was
reduced by 68.9 ± 2.4% compared to the BF8-free control. The similar activities of BF8 on
RP437 and its ΔluxS mutant suggest that persister control by BF8 is at least not solely through
QS inhibition and BF8 may have other target(s).
3.4.2 BF8 sensitized E. coli persisters to antibiotics.
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BF8 was also tested for its effects on persisters isolated from an overnight culture. As shown in
Figure 3-2A, BF8 didn’t exhibit significant effects on the viability of isolated persister cells
(p=0.2519); however, the persister cells were rendered sensitive to Ofl dose-dependently by BF8.
For example, 91.6± 0.3% persister cells were killed by Ofl treatment after incubation with 5
µg/mL BF8 for 2 h (p=0.0018). To test if BF8 can also revert the tolerance of E. coli persister
cells to other antibiotics, representative antibiotics from another two classes of antibiotics were
tested with targets of protein synthesis (Tet, Gen and Tob) and cell wall synthesis (Amp),
respectively. Persister cells isolated from overnight cultures were treated with BF8 at different
concentrations for 2 h and then challenged with these antibiotics. As shown in Figure 3-2B-E,
after treatment with BF8 at 5µg/mL, RP437 persister cells were rendered more sensitive to Tet,
Tob and Gen treatment but not to Amp. For example, at 5 µg/mL, BF8 sensitized isolated
persisters to: Tet by 100.0 ± 0.0% (p<0.0001), Tob by 74.7 ± 3.9% (p=0.0020) and Gen by 79.8
± 6.7% (p=0.0257). We chose 0.85% NaCl solution rather than LB medium for this test because
0.85% NaCl solution does not support growth so that we can study the effects of BF8 on isolated
persister cells specifically. It is worth noticing that the concentrations of BF8 that exhibited
activities are lower in 0.85% NaCl than in LB, presumably because LB medium contains large
molecules that can bind to BF8 and reduce its activities.
3.4.5 Synergy with pH change.
Since change in PMF has been shown to sensitize persister cells to aminoglycosides, we
hypothesized that the effects of BF8 can be enhanced by adjusting the pH during treatment. A pH
range of 6-8.5 was tested and the results are shown in Figure 3-3A. At pH from 6 to 7.5, BF8
didn’t show significant cidal effect on persister cells (p=0.0689); however, BF8 was more
effective in sensitizing persister cells to Ofl when pH increased from 6 to 7 and further more at
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pH 7.5. For example, tolerance to Ofl was reduced by 85.5±0.5% at pH 7.5 compared to pH 6
(p=0.0144). At pH values higher than 7.5, BF8 exhibited cidal effects on persister cells and
further reduced persistence; e.g., at pH of 8, 69.2± 5.4 % persister cells were killed by 1 µg/mL
BF8 and 98.5 ±0.7% of persister cells were rendered sensitive to Ofl compared to pH 6. Overall,
the potency of BF8 to sensitize RP437 persister cells to Ofl was found to increase with pH in the
tested range (pH 6-8.5); and no cidal effect of BF8 was observed for pH values not higher than
7.5. To compare the results, isolated persister cells were also treated with the same buffers with
varying pH without BF8. As shown in Figure 3-3B, in the absence of BF8, persister cells
remained tolerant to Ofl under all the pH values tested (p=0.0663) and no cidal effects were
observed (p=0.9564). Thus, the pH change itself did not affect persistence, but exhibited
interesting synergy with BF8. To determine if this is a true synergy or permanent change in
BF8’s structure in alkaline condition, BF8 was treated at high pH values and then adjusted to pH
6 before it was tested on isolated persister cells. As shown in Figure 3-3C, pH-treated BF8
showed no cidal effect on persister cells (p=0.2674) or the change in the ability to sensitize
isolated persister cells (p=0.3589). So the increase in potency of BF8 at higher pH was indeed
through synergistic effects, rather than permanent changes in BF8’s structure.
3.4.6 BF8 reduced persistence in RP437 biofilms.
We reported previously that BF8 can inhibit biofilm formation of E. coli RP437 at growth-non
inhibitory concentrations (20). In this study, we were interested in further characterizing its
effects on biofilm-associated persister cells. To achieve this goal, RP437 biofilm was grown in
LB medium in the absence and presence of different concentrations of BF8. The number of total
viable cells and the number of persisters were quantified for both the biofilm and planktonic
populations. As shown in Figure 3-4, BF8 reduced biofilm formation of RP437 on stainless steel
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304L coupons, consistent with the report of Han et al. (20) For example, BF8 at concentrations
up to 60 µg/mL showed no cidal effect (p=0.1107). However, BF8 significantly reduced biofilm
formation; e.g., at 30 µg/mL, the total number of biofilm cells was reduced by 93.2 ± 2.3%
(p=0.0197), compared with the BF8-free control. In addition to inhibition of biofilm formation,
BF8 was found to reduce the number of persister cells in both the planktonic and biofilm
populations. For example, at 30 µg/mL, the total number of persisters in planktonic and biofilm
population were reduced by 90.3 ± 2.8% (p<0.0001) and 87.4 ± 3.1% (p=0.0218) respectively,
compared with the BF8-free control.
3.4.7 BF8 reduced the persistence of pre-formed biofilms.
In addition to the effects on biofilm formation and associated persistence, BF8 was also found to
detach RP437 cells from 24-h biofilms and reduce the number of persister cells dosedependently. For example, shown in Figure 3-5, at 5 µg/mL, the viable cells in planktonic phase
were not reduced significantly (p=0.0543); while the number of viable cells in biofilm was
reduced dramatically by 94.4 ± 1.0% (p<0.0001). BF8 also reduced the persister cell number in
both planktonic and biofilm populations. For example, at 5 µg/mL, the number of persister cells
in planktonic population was reduced by 93.1 ± 5.6% (p<0.0001); and the number of viable
persister cells in biofilm was reduced by 99.0 ± 0.1% (p<0.0001).
3.4.8 DNA microarray study.
Treatment of RP437 persister cells with 5 µg/mL BF8 for 1 h was found to induce 6 genes and
repress 10 genes consistently in duplicated (two biological replicates) DNA microarray tests
(Table 1). These results were also confirmed with a Q-PCR study by choosing 6 of these 17
genes, including trpD, cspD, mdaB, yhhW, ybiJ and hcaD (Table 2). It is interesting to note that
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mdaB was induced by BF8. This gene has a homolog PA2580 in P. aeruginosa which was also
induced by BF8 (18).
BF8 repressed ycfR by 15.3 fold compared to the BF8-free control. Deletion of ycfR was reported
to induce more biofilm formation and change E. coli cells from hydrophilic to hydrophobic (27).
Thus, induction of this gene by BF8 is consistent with biofilm inhibition by BF8. Among the
repressed genes, trpABCDE were repressed by 3-4 fold. This operon is involved in tryptophan
synthesis and indole synthesis. It has been reported that deletion mutant of trpE produces 10-fold
less indole than the wild-type (27, 28) and indole has been shown to be signal to promote
antibiotic tolerance in E. coli (7). It will be interesting to further study if indole synthesis is
affected by BF8.
3.5 Discussion
In this study, the effects of (Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one (BF8) on
RP437 and KX1485 were tested. The obtained results show that BF8 could reduce the
persistence during E. coli growth and sensitize the isolated persister cells to Ofl (DNA gyrase
inhibitor), Gen, Tet, and Tob (aminoglycosides), but not Car (β-lactamase). The effects of BF8
were found more effective with increase in pH (pH 6-8.5 tested). In addition to planktonic cells,
BF8 was found to reduce biofilm formation, reduce the number of viable cells of pre-formed
biofilms and reduce the number of associated persister cells.
This study shows that a QS inhibitor BF8 can reduce persister formation during the growth of E.
coli RP437 in LB medium, at the concentrations that have no cidal effects. It has been reported
that one resuscitation-promoting factor can sensitize persister cells of Gram- positive bacteria
(29), and 3-[4-(4-methoxyphenyl)piperazin-1-yl]piperidin-4-yl biphenyl-4-carboxylate can
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sensitize persister cells of Gram-negative bacteria (30) to norfloxacin. Also sugars have been
reported to sensitize both Gram-positive and Gram-negative persister cells to aminoglycoside
(14). Compared to these compounds, BF8 is the first QS inhibitor that has been shown to control
persisters. Interestingly, both in our recent study on P. aeruginosa persisters and in the present
study on E. coli, we obtained data suggesting the activities of BF8 in persister control are not
solely through QS inhibition. The synergy with pH shown in this study indicates that BF8 may
interact with cell membrane.
In a previous study, it was found that PMF from oxidization of NADH facilitates aminoglycoside
uptake by persister cells (14). In this process, quinones(Q), NADH and quinol oxidase are
involved (14). Interestingly, our DNA microarray data show that mdaB encoding a modulator of
drug activity B, a NADPH quinone oxidoreductase, was induced by BF8. This enzyme has a
predicted binding site specific for flavin adenine dinucleotide (FAD) (31), which is an active
redox cofactor and transfers two electrons(31). In addition, the depletion of flavin
mononucleotide pool was considered to cause persister formation (1, 32). This implies that
waking up persister may involve the redox reactions catalyzed by FAD. Besides P. aeruginosa
and E. coli, mdaB is conserved in many other species including Helicobacter hepaticus (33).
Thus, it will be helpful to test if BF8 might show similar effects on other bacterial species. Our
microarray data also showed reduction in cspD. This result is consistent with Kim’s report (34)
that toxin cspD can increase persister formation.
DNA microarray study showed no QS genes were directly affected by BF8. This is expected
because the microarray study was based on dormant persister cells. However the expression of
gene related to indole-production was repressed by BF8; e.g. multiple genes in the trp operon
(trpABCDE) were repressed by 3.0 to 4.7 fold (Table 1).
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Deletion of TrpE has been shown to reduce indole production (28) and indole is a signal known
to stimulate persister formation (35). The results are consistent with the finding in the present
study that BF8 can revert the persistence in E. coli and repress trpABCDE genes. Interestingly,
both indole (28) and BF8 (this study) are inhibitors of E. coli biofilm formation which warrants
further research.
Collectively, the data obtained in this study suggest that BF8 may have multiple targets for
persister control. Further studies on its effects on indole signaling and cell membrane functions
will shed new lights on this interesting phenomenon.
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Tables
Table 1
Gene

Expression ratio*

Gene products/Functions

mdaB

4.3

modulator of drug activity B

ybiJ

15.0

hypothetical protein

ycfR

15.3

Inhibition of ycfR has been shown to reduce biofilm formation (27)_ENREF_28_E

ygiD

6.5

hypothetical protein

yhaK

3.8

hypothetical protein

yhhW

6.1

hypothetical protein

aldA

-2.9

aldehyde dehydrogenase

cdd

-2.8

cytidine deaminase

cspD

-1.7

DNA replication inhibitor

ryeA

-2.7

non-coding RNA (small RNA that interacts with Hfq, a RNA chaperon)

trpA

-3.0

tryptophan synthase subunit alpha

trpB

-4.7

tryptophan synthase subunit beta
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trpC

-3.5

bifunctional indole-3-glycerol phosphate

trpD

-3.9

bifunctional glutamine

trpE

-3.2

anthranilate synthase

udp

-3.8

uridine phosphorylase

* Expression ratio (BF8 vs. control, average of the two biological replicates)

Table 2
Gene

Expression ratio (BF8 vs. control)
DNA microarray

Q PCR

cspD

-1.7

-1.6

trapD

-3.9

-1.9

mdaB

+4.3

+1.4

yhhW

+6.1

+3.2

ybiJ

15.0

+5.0

hcaD

1 (no change)

1 (no change)
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Figure Caption
Figure. 3-1 BF8 reduced persistence during RP437 growth. (A) BF8 reduced the number of
RP437 persisters during growth. RP437 was cultured for 5 h in LB medium supplemented with
BF8 at different concentrations. The total number of cells and the number of persister cells were
normalized by the corresponding BF8-free control. (B) D-glucose and D-mannitol did not affect
persistence. The same experimental procedure was followed by using 10 mM D-glucose or Dmannitol instead of BF8. The number of total cells and the number of persister cells of untreated
controls were normalized as 100%.
Figure. 3-2 BF8 sensitized the persister cells to other antibiotics. BF8 sensitized RP437
persister cells isolated from an overnight culture to different antibiotics. The RP437 persister
cells were isolated from an 18 h overnight culture and treated with different concentrations of
BF8 (0, 0.5, 1, 2, 5 µg/mL) for 2 h in 0.85% NaCl solution. The viability of RP437 was
evaluated by counting CFU and a portion of each sample was then treated with antibiotics to
count the number of RP437 cells that remained as persisters. The tested antibiotics include 5
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µg/mL Ofl (A), 25 µg/mL Tet (B), 25 µg/mL Tob (C), 25 µg/mL Gen (D) and 100 µg/mL Amp
(E). The untreated controls were normalized as 100%.
Figure. 3-3 Synergistic effects between BF8 and pH change. (A) BF8 exhibited higher
activities with increase in pH. The effects of BF8 increased with pH between 6-8.5. The RP437
persister cells were isolated from an 18 h overnight culture and treated with different
concentrations of BF8 for 2 h in PBS with different pH. The viability of RP437 was evaluated by
counting CFU and a portion of each sample was then treated with 5 μg/mL Ofl to count the
number of cells that remained as persisters. The cell numbers were normalized by those at pH of
6. (B) Changing pH alone did not affect persistence. The same experimental procedure was
followed in the absence of BF8. The cell numbers were normalized by those at pH of 6. (C)
Increase in the activity of BF8 is through synergy with pH change rather than permanent change
in BF8’s structure. BF8 was treated with PBS at different pH (6, 6.5, 7, 7.5, 8, 8.5) for 2 h, and
then adjust back to pH of 6 before tested for their effects on RP437 persisters.
Figure. 3-4 BF8 reduced biofilm formation and associated persistence. (A) BF8 reduced
biofilm formation and persister cells inside biofilm during the growth of biofilm. BF8 at different
concentrations was added at inoculation and the biofilms were cultured for 18 h. (B) E. coli
RP437 was cultured with BF8 at different concentrations (0, 5, 10, 30 and 60 µg/mL) for 18 h.
Biofilm formation was reduced at growth-non inhibitory concentrations.
Figure. 3-5 BF8 is effective against pre-formed biofilm. BF8 reduced the total cell number and
persister number in both planktonic population and biofilm population. The 18-h biofilms were
treated with BF8 at different concentrations for 12 h in 0.85% NaCl solution.
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Figure 3-6. Comparison of persister levels of RP437 and KX1485 after 5 h of growth. The
subcultures of RP437 and KX1485 were grown for 5 h and the total cells and persister cells were
quantified. The results show these two strains have the same level of persistence.
Figure 3-7. Concentration and treatment time of ofloxacin (Ofl) for persister isolation. (A)
Effects of Ofl concentration on the viability of RP437 cells. RP437 cells from an 18 h culture
were challenged with different concentrations of Ofl for 3.5 h. Then the number of cells that
remain viable was determinated by counting CFU. (B) Effects of treatment time on the viability
of RP437 cells. RP437 cells from an 18 h culture were incubated with 5 µg/mL Ofl for different
lengths of time. The number of cells that remained viable was determined by counting CFU. The
results indicate that treatment with 5 µg/mL Ofl for 3.5 h is sufficient for isolating persister cells
of RP437.
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Chapter 4
CONTROLLING PERSISTER CELLS OF Pseudomonas
aeruginosa PDO300 BY (Z)-4-BROMO-5-(BROMOMETHYLENE)3-METHYLFURAN-2(5H)-one

This chapter has been submitted as below with minor modifications. Jiachuan Pan, Fangchao
Song and Dacheng Ren. Controlling persister cells of Pseudomonas aeruginosa PDO300 by (Z)4-bromo-5-(bromomethylene)-3-methylfuran -2(5H)-one. Bioorganic & Medicinal Chemistry
Letters. 2013.
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4.1 Abstract
Pseudomonas aeruginosa is a major pathogen causing chronic pulmonary infections; e.g., 80%
of cystic fibrosis patients get infected by this bacterium as the disease progresses. Such chronic
infections are challenging because P. aerugionsa exhibits high-level tolerance to antibiotics by
forming biofilms (multicellular structures attached to surfaces), by entering dormancy and
forming persister cells, and by conversion to the mucoid phenotype. Recently, we reported that a
synthetic quorum sensing inhibitor, (Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one
(BF8), can sensitize the persister cells of P. aeruginosa PAO1 to antibiotics at the concentrations
non-inhibitory to its growth. In this study, we report that BF8 has cidal effects on the mucoid
strain P. aeruginosa PDO300, a mucA22 derivative of PAO1, and has synergistic effects in
killing PDO300 with antibiotics. These results broaden the activities of this class of compounds
and indicate that BF8 also has other targets in P. aerugionsa in addition to quorum sensing.

Keywords: antibiotic tolerance, persister, quorum sensing, biofilm, PDO300
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4.2 Introduction
Persister cells are commonly found as a small subpopulation in a bacterial culture, which is
metabolically inactive and highly tolerant to antibiotics1. Such intrinsic tolerance is not acquired
through drug resistance genes, but can also lead to chronic infections with reoccurring symptoms
after the course of antibiotic therapy1, which facilitate the development and wide spread of
acquired multidrug resistance based on genetic mutations and horizontal gene transfer.
High persistence mutants of P. aeruginosa have isolated from sputa of cystic fibrosis patients2. In
this autosomal recessive genetic disorder, the loss of function of transmembrane conductance
regulator (CFTR) leads to overproduction and accumulation of mucus in the breathing passages
of patients’ lungs 3. This condition is favorable to the adherence of bacteria, such as P.
aeruginosa, and formation of multicellular structures with cells embedded in a polysaccharide
matrix, known as biofilms. Both biofilm cells and persister cells are highly tolerant to
antibiotics4,5.
Another important factor of pathogenesis is the conversion of P. aeruginosa to the mucoid
phenotype, which is characterized by overproduction of the polysaccharide alginate and
enhanced antibiotic tolerance6,7. Conversion to mucoid strain occurs due to mutations in P.
aeruginosa genes, such as algU8, mucA7, and mucB9, and plays an important role in the
establishment of chronic infection of this pathogen with high mortality and morbidity6.
Recently, we reported that (Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one (BF8), an
inhibitor of bacterial quorum sensing (a system that regulates bacterial gene expression in
response to their cell density), can sensitize the persister cells of P. aeruginosa PAO1 to
antibiotics at growth non-inhibitory concentrations. To further understand persister control by
BF8, we tested its effects on the persister cells of a mucoid strain P. aeruginosa PDO300. P.
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aeruginosa PDO300 is a mucA22 derivative of PAO1 induced by reactive oxygen species
(ROS)7. To our best knowledge, this is the first effort to study the effects of a quorum sensing
inhibitor on the persistence of a mucoid strain.
4.3 Material and Method
4.3.1 Furanone Synthesis.
(E)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one (BF8) was synthesized as described
previously10,11, dissolved in absolute ethanol as 60 mg/mL, and stored at 4°C until use.
4.3.2 Bacterial strain and growth media.
P. aeruginosa PDO300 (henceforth PDO300) and PAO1 (henceforth PAO1) were routinely
grown in Luria-Bertani (LB) medium12. The LB medium was also used to form biofilms. To
isolate persister cells, 18-h overnight cultures were treated with 200 µg/mL ciprofloxacin (Cip)
for 3.5 h at 37oC with shaking at 200 rpm (unless otherwise specified), washed twice with 0.85%
NaCl solution to remove carryover of antibiotics, and then resuspended in 0.85% NaCl solution.
The cell-washing steps mentioned above were performed by centrifugation at 13,200 rpm for 3
min at room temperature and then resuspended in 0.85% NaCl solution. The drop plate method
described by Chen et al.13_ENREF_15_ENREF_14_ENREF_14 was followed to count colony
forming units (CFUs). One-way ANOVA followed by Tukey test was applied for statistical
analysis to test the significance.
4.3.3 Effects of BF8 on persister formation.
A PDO300 overnight culture was used to inoculate subcultures in 5mL fresh LB medium to an
initial optical density at 600 nm (OD600) of 0.05. Then the subcultures were supplemented with
122

different concentrations of BF8 (0, 5, 10 and 30 µg/mL) immediately. The amount of ethanol
(solvent of BF8 stock solutions) was adjusted to be the same in each sample to eliminate any
solvent effect. Samples were taken after 5 h or 12 h of incubation and the total cell number in
each sample was quantified by counting CFU. Meanwhile, persisters were isolated from the
remaining portion of each sample. The number of persisters formed after 5 h or 12 h growth was
quantified by counting CFU.
4.3.4 Effects of BF8 and AHLs on the susceptibility of PDO300 persister cells to Cip.
PDO300 persister cells were isolated from 18-h overnight cultures as described above. Isolated
persister cells were diluted by 50 times with 0.85% NaCl solution and then each 3 mL of diluted
persister cells was challenged with varying concentrations of BF8 (0, 5, 10, 25 and 50 µg/mL).
Ethanol (the solvent used for making BF8) was adjusted to be the same in all the samples to
eliminate any solvent effect. After incubation for 2 h at 37oC with shaking at 200 rpm, 1 mL of
each sample was taken and washed three times with 0.85% NaCl solution to quantify the total
number of viable cells by counting CFU. Meanwhile, the persister cells in the remaining portion
were isolated after additional treatment with 200 µg/mL Cip, diluted and plated on LB agar
plates to quantify the number of cells that remained as persisters.
4.3.5 Effects of BF8 on persister formation in biofilms.
PDO300 overnight cultures were used to inoculate subcultures in LB medium supplemented with
different concentrations of BF8 (0, 20, 40 and 60 µg/mL) to an OD600 of 0.05. The amount of
ethanol was adjusted to be the same in all the samples to eliminate any solvent effect. In each
subculture, 2 cm × 1 cm 304L stainless steel coupons were put at the bottom of the petri dish to
form biofilms. After 18 h of biofilm growth at 37oC without shaking, stainless steel coupons with
123

biofilm were rinsed gently with 0.85% NaCl solution and soaked into 5 mL 0.85% NaCl
solution. Then then biofilm cells were mechanically detached by vortexing for 1 min and
sonicating (Ultrasonic cleaner Model No B200, Sinosonic Industrial Co., Ltd, Taipei Hsien,
Taiwan) for 1 min (repeat once)14,15. Detached biofilm cells were plated on LB plates to count
CFU and the rest of the samples were used for persister isolation as described above. Meanwhile,
1 mL planktonic cells from each subculture was washed three times and plated on LB agar plates
to determine the viability of total planktonic cells by counting CFU. Another 1 mL from
planktonic cells in each subculture was sampled for persister isolation. The persister samples
from the above treatment were diluted and plated on LB agar plates to determine the number of
persister cells in each planktonic or biofilm sample.
4.3.6 Effects of BF8 on persister cells in established biofilms.
PDO300 overnight cultures in LB medium were used to inoculate subcultures in LB medium to
an OD600 of 0.05. Coupons of 304L stainless steel (2 cm × 1 cm) were placed in petri dishes
containing above PDO300 culture. After 18 h of incubation, the coupons with established
biofilms were transferred to a 12 well plate (Becton Dickinson, Franklin Lakes, NJ,). Each well
contained 4 mL of 0.85% NaCl solution supplemented with different concentrations of BF8 (0, 2,
5, 10 and 30 µg/mL). The biofilm samples in 12 well plates were incubated at 37°C for 24 h
without shaking. After 24 h of treatment, 1 mL of medium in each well was sampled, washed
three times with 0.85% NaCl solution and plated on LB agar plates to determine the viability of
RP437 cells by counting CFU. At the same time, another 1 mL of medium was sampled and
persister cells were isolated as described above. To collect the biofilm cells, the coupons were
transferred to 15 mL falcon tubes, each containing 5 mL 0.85% NaCl solution. The biofilm cells
were detached by vortexing for 1 min and sonicating for 1 min (repeat once)14. Detached biofilm
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cells were diluted and plated on LB plates to count CFU and the persister cells in the rest of the
samples were isolated as described above. The isolated planktonic persister cells and biofilmassociated persister cells were diluted and plated on LB agar plates to count CFU.
4.4 Results:
4.4.1 BF8 exhibited different effects on PDO300 and PAO1 persister cells.
Recently (Chapter 2), we demonstrated the BF8 can reduce persister formation during 5 h of
PAO1 growth in LB medium11. In comparison, BF8 showed no effect on the viability (p=0.1647)
and persister formation (p=0.0838) of PDO300 during the 5 h growth; however, with longer
treatment time (12 h), BF8 reduced the persister formation without growth inhibition (Figure 42). For example, after 12 h of incubation, BF8 did not affect the growth of PDO300 [Figure 42(B), p = 0.4079], but reduced the persister level dose-dependently [Figure 4-1B, p=0.0038]. For
example, at 30 µg/mL, BF8 reduced number of persisters by 88.5±4.3% (p=0.0014) compared to
the BF8-free control (Figure 4-1B).
4.4.2 BF8 is cidal to PDO300 persister cells.
As described in Chapters 2 and 3, BF8 can sensitize isolated persister cells of PAO1 and E. coli
RP437 to antibiotics without affecting the viability. Interestingly, we found that BF8 can directly
killed PDO300 persister cells at the concentrations of 5 to 50 µg/mL (Figure 4-3, p<0.001). For
example, at 5 µg/mL, BF8 killed PDO300 persister cells by 80.9 ± 1.9% (p=0.0064) and the
remaining viable persister cells were not sensitized to Cip. At higher concentration of BF8, e.g.,
50 µg/mL, BF8 killed all the isolated persister cells.
4.4.3 BF8 reduced biofilm formation and the number of persister cells inside biofilm.
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BF8 was reported to be an inhibitor of quorum sensing and biofilm formation of P. aeruginosa
PAO1 11,16 5. Here, we show that BF8 can also dose-dependently reduce the biofilm formation of
PDO300 and the number of persister cells in its biofilms (Figure 4-4A). At all the concentrations
tested, BF8 didn’t reduce the number of viable cells in the planktonic phase (p=0.1526), but
reduced biofilms dose dependently (p=0.0002). For example, at 60 µg/mL, biofilm formation
was reduced by 91.6 ± 0.5% (p<0.0001). In addition, the number of viable persister cells inside
the biofilms was reduced by 98.3 ± 0.7% (p=0.0003). Consistent with the results shown in Figure
4-2B, the number of viable persister cells in planktonic cells were also reduced dose-dependently
by BF8 (p<0.0001). For example, at 60 µ/mL, the number of persister cells was reduced by 96.5
± 1.3% (p<0.0001).
4.4.4 BF8 is also effective against PDO300 in established biofilms.
Treatment of 18-h PDO300 biofilms with BF8 was found to reduce the number of viable biofilm
cells dose-dependently (Figure 4-4B, p=0.0031] and kill the persister cells in biofilms [Figure 44B, p=0.0288]. For example, after treatment with 30 µg/mL BF8 for 24 h, no viable cells were
detected in the planktonic phase; and only 0.01±0.01% biofilm cells remained on the surface
were viable (p= 0.0024) with no viable persister cells were detected. Compared with the results
about PAO111, the results in this chapter indicate that BF8 is more effective against PDO300
biofilms than PAO1 biofilms.
4.5 Discussion
In this study, we should that BF8 can also control persister cells of the mucoid strain P.
aeruginosa PDO300. It is an interesting finding that a longer treatment time is needed for BF8 to
significantly reduce persistence during PDO300 growth. This may be due to the presence of
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alginate, which could retard the penetration of BF8. It is also interesting to find that, at the
minimum concentration to control persistence, BF8 has cidal effects against PDO300 persister
cells in 0.85% NaCl buffer, but not in LB medium. Different from the effects on PAO1 persister
cells, BF8 at 5 to 50 µ/mL killed PDO300 persister cells directly without synergic effect with
further Cip treatment. The underlying mechanism is unknown; however, since overproduce of
alginate is major phenotypic difference between PAO1 and PDO300, alginate may be an
important factor 7. Alginate (Figure 4-1B) can be deprotonated at high pH (>6.5) 17 and become
negatively charged. Since alginate is around PDO300 cells18, it is possible that the change in the
charge of alginate and local pH may influence the interaction between BF8 and PDO300 cells
and cause cidal effects in 0.85% NaCl solution. In Chapter 4, we described that BF8 is more
effective against E. coli RP437 persister cells in PBS when pH increased slightly above 7. Thus,
it will be important to investigate the effects alginate on the pH around cells, and associated
changes in proton motive force, and the mechanism/target of persister control by BF8.
Overall, the finding described in this Chapter present additional activities of this class of quorum
sensing inhibitors and indicate the existence of other targets in P. aerugionsa. Further study
about the underlying mechanism will help understand bacterial persistence and develop effective
approaches to control P. aerugionsa infections with mucoid strains.
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Figure captions
Figure 4-1 Structures of BF8 (A) and alginate deprotonated at pH of 6.5 (B).
Figure 4-2. BF8 reduced persister formation during PDO300 growth, but required a longer
time of treatment than PAO1. (A) BF8 did not significantly reduce persistence during 5-h
treatment. (B) BF8 reduced the persistence of PDO300 dose-dependently after treatment for 12
h.
Figure 4-3. BF8 exhibited cidal effects against PDO300 persister cells in 0.85% NaCl
solution.
Figure 4-4. Effects of BF8 on PDO300 biofilms and associated persister cells. (A) BF8
reduced biofilm formation in LB medium and the number of biofilm-associated persister cells at
concentrations that did not affect the viability of planktonic cells. (B) BF8 can kill PDO300
persister cells in established biofilms when treated in 0.85% NaCl solution.
Figure 4-5. Effects of 3-oxo-C12-AHL and C4-AHL on isolated PDO300 persister cells. (A) 3oxo-C12-AHL sensitized PDO300 persister cells without compromising viability. (B) C4-AHL at
the same concentration did not sensitize persister cells or reduce the viability of persister cells.
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Figure 4-1
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Figure 4-2
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Figure 4-3
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Figure 4-4
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Figure 4-5
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Chapter 5
STRUCTURAL EFFECTS ON PERSISTER CONTROL BY
BROMINATED FURANONES

This chapter has been submitted as below with minor modifications. Jiachuan Pan, Fangchao
Song and Dacheng Ren. Structural effects on persister control by brominated furanones.
Bioorganic & Medicinal Chemistry Letters. 2013.
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5.1 Abstract
In chapter 2, 3 and 4, we reported that a quorum sensing (QS) inhibitor, (Z)-4-bromo-5(bromomethylene)-3-methylfuran-2(5H)-one (BF8) can restore antibiotic susceptibility of
Pseudomonas aeruginosa PAO1 persister cells. In this chapter, a group of synthetic brominated
furanones with similar structures was tested to identify for potential persister control. The results
show that these furanones are QS inhibitors and can also restore the antibiotic susceptibility of P.
aeruginosa PAO1 persisters.
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5.2 Introduction
Persister cells are phenotypic variants that can be found in virtually any bacterial and are tolerant
to different antibiotic treatments1. Consistently, bacterial strains with high-level persistence have
been isolated from patients with cystic fibrosis and tuberculosis [].
Recently, it is reported that (Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one (BF8)
can revert antibiotic tolerance of Pseudomonas aeruginosa persister cells3. BF8 is an inhibitor of
bacterial quorum sensing (QS)3, 4, a gene regulation system in response to bacterial population
and regulates different phenotypes5 such as biofilm and bioluminescence. Although this QS
inhibition also controls P. aeruginosa persister cells, the role of QS in persister formation
remains elusive. The QS signal 3-oxo-C12-HSL (AHL) has been shown to promote persister
formation in exponential culture of P. aeruginosa. However, adding spent media was not found
to enhance persistence in Escherichia. coli. We also found that can sensitize P. aeruginosa
persister cells. Thus, comparison test of BFs with similar structures for their effects on persisters
and QS will provide useful information for understanding the activities of BFs and designing
better control method.
Han and coworkers characterized a group of synthetic BFs with related structures and identified
important structural elements for biofilm control. Here we test their effects on QS and
persistence of P. aeruginosa.
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5.3 Material and Method
5.3.1 Effects on AHL- mediated QS.
The QS reporter V. harveyi BB886 [ATCC (BAA-1118)] was used to characterize the effects of
BFs on QS. This strain produces bioluminescence in response to AHL8. The procedure as
described by Surette and Bassler was followed with slight modifications. Briefly, V. harveyi
BB886 was grown in AB medium overnight and then diluted by 1:5000 with the fresh AB
medium. After incubation for 5.5 hours, subculture was added with a brominated furanone or
non-brominated furanone. Concentrations of 0, 0.1, 0.5, 1, 10, 30 and 60µg/mL were tested for
each furanone. After 1.5 h of incubation, the bioluminescence was measured using a
luminometer (Turner Biosystem 20/20n); and then the cells from each sample were washed by
centrifugation and resuspension in 20g/L NaCl solution to count CFU.
5.3.2 Effects of BFs on persistence.
The BFs tested in our study exhibited different activities in restoring the susceptibility of P.
aeruginosa PAO1 to ciprofloxacin. The persisters were isolated by adding 200µg/mL
ciprofloxacin to an 18 h overnight culture and incubating at 37oC with shaking at 200 rpm. Then
the cells were washed three times to remove the antibiotic residue and resuspended in 0.85%
NaCl solution with 50 times dilution. The tested BF was added to the cell suspension and
incubated for 2h. One mL of BF-treated persisters was washed three times and plated on LB agar
plates for counting CFU. Another portion of BF-treated persisters was added with 200 µg/mL
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ciprofloxacin and incubated for 3.5 h to determine the number of cells that remained as persisters.
The amount of ethanol was adjusted to be the same for all samples to eliminate any solvent effect.
5.4 Results
5.4.1 Effects on AHL- mediated QS.
As shown in Figure 5-2A, addition of BF9 reduced bioluminescence dose-dependently with no
effects on the viability of V. harveyi BB886 observed when BF9 was added up to 10µg/mL. For
example, the bioluminescence was reduced by 99.96±0.69% when BF9 was added as 10µg/mL.
At higher concentrations, e.g. 30 µg/mL, the viability of V. harveyi BB886 was reduced by BF9
and no bioluminescence was detected. BF11 and BF12 also exhibited similar activities:
inhibiting QS without affecting the viability of the reporter strain when the concentration is
below a threshold (Figure 5-2). For example, at 0.5µg/mL, BF9, BF11 and BF12 reduced the
relative bioluminescence (bioluminescence/CFU of the V. harveyi BB886) by 84.7±13.6%,
55.9±0.3% and 91.2±4.3%, respectively.
For comparisons in this test, two non-brominated furanones (purchased from ATCC) were
included as controls. Shown in Figure 5-1G and Figure 5-2G, NF1 was found toxic to V. harveyi
BB886 at 1µg/mL or higher concentrations and NF2 (Figure 5-1H and Figure 5-2H) did not
affect the viability and QS of V. harveyi BB886 at concentrations up to 60µg/mL. This result
indicates that the bromine atoms are important to QS control by BFs.
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5.4.2 Effects of BFs on persistence.
As shown in Figure 5-2, BF11 at certain concentrations showed the capability to sensitize
persister cells to ciprofloxacin without reducing the viability of persister cells. For example, after
treatment with BF11 at 2 µg/mL, 99.99±0.02% PAO1 persisters were killed by ciprofloxacin.
But BF11 at 2 µg/mL by itself did not affect the viability.
In comparison, BF10, BF12 and BF13 can kill PAO1 persister cells directly and exhibited
synergistic effects with Cip in killing persister cells. BF10, BF13 and BF12 at 2µg/mL killed
PAO1 persister cells by 99.9±0.0%, 98.9±0.2% and 93.0±0.1%, respectively.
5.5 Discussion
Recently, Allison et al10 reported that sugars, such as glucose, mannitol, fructose and pyruvate
can potentiate metabolically E. coli persisters to aminoglycosides. As shown in Figure S1,
glucose at 2µg/mL does not affect the viability or antibiotic tolerance of PAO1 persisters. The
non-brominated furanones NF1 and NF2 also did not exhibit notable effects (Figure 5-3G&H).
Although the mechanism of persister control by BFs is still unknown, the differences in QS and
persister control by BFs suggest that these compounds also have other targets in P. aeruginosa.
BF8 could induce a repressor of the P. aeruginosa toxin Cif, toxin which interferes with a
ubiquitin proteolytic system of its host and degrades the cystic fibrosis transmembrane
conductance regulator (CFTR) in mammalian cells, increasing the chance for cystic fibrosis11, 12.
Thus, these BFs and other similar compounds may have activities to control related chronic
infections. Further study with animal cells/ animal models will provide valuable information for
infection control by targeting persister cells.
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Figure caption
Figure 5-1 Structures of brominated furanones and non-brominated furanones used in this
study.
Figure 5-2 Effects of BFs on AHL-mediated quorum sensing. V. harveyi BB886 was
challenged by BFs and NFs at different concentrations. The number of viable V. harveyi BB886
cells after BF treatment and the bioluminescence are shown. The relative bioluminescence
normalized by CFU is also shown for the convenience of comparison.
Figure 5-3 Effects of BFs and NFs on isolated PAO1 persister cells. After treatment for 2 h,
the number of surviving persisters was quantified by CFU. Meanwhile, a portion of each sample
was further challenged with 200µg/mL Cip for 3.5 h to determine the number of cells that
remained as persister by counting CFU.
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Figure 5-1
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Figure 5-2
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Figure 5-3
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APPENDIX
Experimental protocols
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Protocol 1
Synthesis of (Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one (BF8)
This protocol is developed based on the procedures described by Han et al [1]. The major steps
are: Br addition, ring-closing reaction; and purification using chromatography.
Cleaning glassware
All glassware should be thoroughly cleaned, leaving on oil or salt stains (including irons) and
dried in an oven before use..
1. Clean the glassware with acetone to move organic chemicals.
2. Clean the glassware with soap and water to move salts.
3. Wash with acetone again.
4. Dry in an oven.
I Br addition
The device is set up as shown in Figure A1. Adjust the T (temperature) to be around 35~40ºC.
Prepare 200 mL ice.
1. Take alpha-methyllevulinica acid from refrigerator (4oC) and keep it at room temperature for
around 30 min before weighting to avoid water condensation.. Add 2.53g alpha-methyllevulinica
acid in the round-bottom flask.
3. Add 20mL dichloromethane (DCM) in the round bottom flask.
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5. Add 20mL DCM to a funnel (addition, graduated), followed by 1 mL of Br2 Double gloving is
highly recommended for this step due to the corrosiveness of Br2.
6. Add Br2 dropwise into the round-bottom flask.
7. After 1 h of relax, check how much of the starting material has reacted using TLC (EA:
Hexane=1:2). If the reaction is complete, go to the next step. Otherwise, more time should be
given for the reflax.
8. Stop the reaction by pouring all the products onto ice in a beaker around 200mL.
II Extract
1. Extract the residue with DCM (3×80 mL)..
2. Add Na2S2O3 (1M, 100 mL, 15.8g) to the extract to remove any Br2.
3. Washing the extract once with DI water (80mL)
4. Dry the extract with anhydrous sodium sulfate by putting anhydrous sodium sulfate into
extract and waiting for 30 min.
5. Filter the extract from the salt by using a funnel with cotton in the middle.
6. Using rotary evaporator to get crude keto.
7. Weigh the product and calculate the yeild (W2)
III Ring-Closing reaction
The device is set up as shown in Figure A1. Adjust the T (temperature) to be around 110ºC1.
Add concentrated H2SO4 (95~98%, 10 mL) to the crude keto at room temperature.
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2. The round-bottom flask with mixture in is heated in an oil-bath at 110ºC for 20 min.
3. Before stopping the reaction, check if the material has all reacted by TLC (DCM: Hexane=1:4,
twice). If so, go on to the next step.
4. Stop the reaction by pouring all the products into a beaker of ice (around 200mL).
IV Extract
1. Extract the products with DCM (3×50 mL). 2. Wash the extract once with DI water (80mL).
3. Dry the extract with anhydrous sodium sulfate.
4. Filter the extract from the salt by using a funnel with cotton in the middle.
5. Remove the solvent using a rotary evaporator .
6. Weigh the product to calculate the yield.
V Purification using chromatography
Set up the device as shown in Figure A2.
3. Mix silicon powder with hexane, and pour into the column. Make sure that the top surface of
silicon is flat.
4. Using compressed air to make the silicon layer tight and without any bubble.
5. Load the sample in the column slowly.
6. Add washed sea sand on the top.
7. Start chromatography with DCM: Hexane = 1:4 as the mobile phase.
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8. Collect the the elute and use TLC (DCM: Hexane=1:4) to check the yield ad purity of the
product.
Reference
[1] Yongbin Han, Shuyu Hou, Karen A. Simon, Dacheng Ren, and Yan-Yeung Luk "Identifying
the important structural elements of brominated furanones for inhibiting biofilm formation by
Escherichia coli" Bioorganic & Medicinal Chemistry Letters. 2008, 18: 1006-1010.
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Thermometer

Gently covered, no pressure, no
seal
Round bottom flask:
200mL

Stir bar
Mineral Oil
Stir bar

R

T

Span R is for spin adjustment;
Span T is for heat adjustment.

H

Span H is for height

Iron support

Figure A1 Device for Br addition and Ring-Closing reaction
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Mobile phase

Sea sand
Sample

10 cm

Silicon gel

Cotton

FigureA2 Device for purification using chromatography
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Protocol 2.
RNA Isolation from Persister Cells
Harvesting Cells
1. Grow 100 mL overnight culture of PAO1/RP437 for 18 h.
2. Collect cells using centrifugation and treat the cells with 200 µg/mL Cip. (for
P.aeruginosa PAO1) or 5 µg/mL Ofl. (for E.coli RP437) for 3.5 hto kill regular cells .
3. Wash persister cells twice with 0.85% NaCl solution.
4. Dilute the persister suspension by 5 times with 0.85% NaCl solution and divide the
diluted culture into two flasks, and the final volume of 0.85% NaCl solution is adjusted to
250 mL.
5. Treat the persister cells with conditions of interest.
6. During treatment, cool all the tubes and centrifuge rotor to 0-4ºC.
7. Collect the persister cells by centrifugating10,000 rpm for 6 min and decant supernatant.
8. Resuspend the cells with cold ice and transfer the cells to a cold 2 mL bead beater tube.
9. Centrifuge
10. Freeze the cells in a dry-ice/ethanol bath and store the cells at -80oC until RNA isolation.

RNA Isolation using RNeasy Mini Kit (Qiagen:74104)
Preparation:
1. Add 200uL Zirconia/Silica beads to each bead beater tube with cells & cool on ice
2. RLT Buffer: 10 µL 2-mercaptoethanol (βME) per 1 mL RLT buffer (2 mL/sample)
3. RPE Buffer: 8 mL EtOH per 2 mL RPE buffer (4 mL/sample)
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4. DNase Mix: 45 µL DNase I stock per 315 µL RDD Buffer (360 µL /sample)

Isolation:
1. Add 900 µL RLT Buffer to the bead beater tube with cell pellet/beads
2. Beat for 60s (set timer at 6) at speed setting of 48 (~5000 rpm).
3. Centrifuge for 15s at 13000rpm at 4C
(All centrifuge steps were carried under this condition unless noted)
4. Collect the supernatent, add 445 µL EtOH
5. Load 700 µL sample onto RNeasy column (Qiagen) and centrifuge
6. Add 350 µL RW1, centrifuge twice
7. Add 180 µL DNase I incubation mix directly onto the column
8. Incubate at RT for 30min
9. Add 350 µL RW1 and centrifuge(repeat once)
10. Add 500 µL RPE and centrifuge (repeat twice)
11. Add 500 µL RPE and centrifuge for two min
12. Replace collection tube and centrifuge for 1m
13. Place the column in a 1.5 collection tube
14. Add 40 uL RNase-free water and centrifuge for 1m; collect the flow-through (repeat
once)
RNA Clean-up
1. Add 900 µL RLT Buffer to previously collected RNA sample
2. Add 445 µL EtOH.
3. Load 700 µL sample onto RNeasy column (Qiagen), centrifuge
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4. Add 350 µL RW1, centrifuge (x2)
5. Add 180 µL DNase I incubation mix directly onto membrane
6. Incubate at RT for 30m
7. Add 350 µL RW1, centrifuge(x2)
8. (x3) Add 500 µL RPE, centrifuge
9. Add 500 µL RPE, centrifuge 2m
10. Replace collection tube, centrifuge 1m
11. Place column in 1.5 collection tube
12. (x2) Add 40 uL RNase-free water, centrifuge 1m
Save flow-through!

Quantification
1. Measure OD at 260 nm and 280 nm (using TE as the background)
Yield: OD260 of 1.0 = 40 ug/mL
Ratio: OD260/OD280 should be >2.0
2. Check the samples on a 1.4% agarose gel
Should have two clear bands (23S at 3.1kb, 16S at 1.5kb)
Smear patterns at low molecular range indicate RNase contamination
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